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ABSTRACT 
ENGINEERING PROBES TO DETECT CHOLESTEROL 
ACCESSIBILITY ON MEMBRANES USING PERFRINGOLYSIN O 
MAY 2014 
BENJAMIN B. JOHNSON  
B.A., UNIVERSITY OF MASSACHUSETTS AMHERST 
PH.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Alejandro P. Heuck  
 Cholesterol is an essential component of mammalian cell membranes and 
it is important to regulate the structure and function of lipid bilayers. Changes in 
cholesterol levels are involved in many physiological and pathological events 
such as the formation of arterial plaques, viral entry into cells, sperm capacitation, 
and receptor organization. Determination of cholesterol trafficking and 
distribution is essential for understanding how cells regulate cholesterol.  
A key factor in the regulation of cholesterol is cholesterol accessibility. 
Through it interactions in the membrane, cholesterol is sequestered below the 
surface of the membrane. Based on the composition of the membrane, a certain 
amount of cholesterol can be solubilized through interaction with the membrane. 
The remaining cholesterol is more solvent exposed and therefor accessible to 
interact with molecules outside of the membrane.  This accessible cholesterol is 
 vi 
 
thought to regulate cholesterol homeostasis within the cell.  A cholesterol probe 
capable of distinguishing changes in cholesterol accessibility within membranes 
would facilitate investigations in this area. 
Perfringolysin O (PFO) is a cytolysin secreted by Clostridium perfringens 
that requires cholesterol in the target cell membrane for binding. The specificity 
of PFO for high levels of accessible cholesterol makes this toxin a potential tool 
for the detection of cholesterol distribution and trafficking. In an effort to adapt 
PFO into a molecular probe capable of sensing changes in membrane cholesterol 
accessibility, I have taken a non-lytic derivative of PFO and introduced several 
point mutations in the membrane-interacting domain 4 loops. These mutations 
altered the threshold of cholesterol concentration required in the membrane to 
trigger binding. 
The cholesterol-dependent binding of each PFO derivative was tested on 
model membranes containing different percentages of cholesterol. Three PFO 
derivatives were selected to test their binding to macrophage plasma membranes. 
These three derivatives showed differential binding to cell membranes treated 
with β-methyl-cyclodextrin/cholesterol mixtures.  These data showed that the 
produced PFO derivatives differentially bind to model and biological membranes 
containing different cholesterol accessibility. 
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CHAPTER 1 
INTRODUCTION 
1.1 Cholesterol 
 Cholesterol is a sterol that is essential for the viability of mammalian cells, 
as it is an important structural component of mammalian cell membranes.  It helps 
to regulate membrane fluidity and stability, as well as reduce membrane 
permeability. Cholesterol is also the precursor to a number of steroid hormones, 
bile acids, and vitamin D.   
 Mammalian cells obtain cholesterol through two distinct pathways; one 
extracellular and one intracellular.  The extracellular pathway involves the uptake 
of cholesterol from the blood stream via receptor-dependent binding of 
lipoproteins.  The intracellular path involves cholesterol synthesis from within the 
cell in the endoplasmic reticulum (ER) from acetyl-CoA.  Both of these pathways 
are tightly regulated respectively to each other and the needs of the cell. 
Cholesterol is unevenly distributed throughout cellular membranes, being largely 
localized on the plasma membrane and less so in the organelles. This distribution 
is important for many cellular functions and is maintained by a large number of 
tightly regulated processes within the cell 
1.1.1 Cholesterol in health and diseases 
Cholesterol, in addition to being an important structural component of cell 
membranes, has been shown to be involved in many physiological and 
pathological events such as the formation of arterial plaques, viral entry into cells, 
and receptor organization. Misregulation of cholesterol can lead to many disease 
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states, the most prominent of which is atherosclerosis.  Atherosclerosis is 
associated with cholesterol metabolism that results in the formation of arterial 
plaques and, thus, the overall hardening of the arteries in humans. The primary 
cause of these plaques is the improper removal of cholesterol from the cells. 
Atherosclerosis is the number one cause of heart disease, the leading cause of 
deaths worldwide.   
While not as prevalent as atherosclerosis, there are a large number of 
diseases caused by deficiency in cholesterol transport. Some examples of these 
are Niemann-Pick type C disease, familial hypercholesterolemias, Wolman 
disease, Tangier disease, Sitosterolemia, Smith-Lemli-Opitz syndrome, 
Cerebrotendinous xanthomatosis, congenital lipoid adrenal hyperplasia, and 
hypobetalipoproteinemias [1].   Niemann-Pick disease, for example, is a lysomal 
storage disease that is caused by the mutation of a cholesterol transport protein 
Niemann-Pick disease, type C (NPC1 or 2) that aids in the uptake of dietary 
cholesterol by moving it out of the late endosome for transport to the ER [2].  
Niemann-Pick disease, while not very prevalent like all of the diseases listed 
above, is very serious and results in a progressive neurological decline followed 
by premature death.   
Many other prominent diseases have been linked to cholesterol 
misregulation as these diseases result in abnormal cholesterol levels and 
distribution, but, at this time, it is still unclear whether misregulation of 
cholesterol causes or is merely just a result of the particular disease state.  
Alzheimer’s Disease and some cancers are among those linked in this way [3]. 
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While evidence of causality is still scarce, some have gone as far as to suggest 
cholesterol reducing drugs as a potential treatment for some cancers [2].  
1.1.2 The role of cholesterol in mammalian cell membranes  
 Cholesterol consists of a hydroxyl group, four planar fused hydrocarbon 
rings, and a hydrocarbon tail (Fig. 1.1A).  The hydroxyl group, in addition to 
mediating interaction with other membrane components, is important for 
orientation of the non-polar portions of the molecule [1].  In the membrane, 
cholesterol situates itself slightly below the surface of the membrane with the 
hydroxyl group interacting with the phospholipid head groups and the non-polar 
tail interacting with the tails of the other membrane components, mainly 
phospholipids and sphingolipids (Fig. 1.1B).    
The interaction of cholesterol with membrane phospholipids and 
sphingolipids adjusts the melting temperature of the membrane to eliminate the 
liquid crystal phase transition in the host membrane. This creates an intermediate 
state in which the membrane has increased fluidity of the hydrocarbon chains 
below the transition temperature and decreases the fluidity above it [1].    At most 
biological temperatures, increases in cholesterol concentration will increase the 
order of the membrane and lower the motion of the hydrocarbon chains.  This 
leads to an increase in packing and mechanical strength, as well as a resulting 
decrease in membrane permeability.  These effects on the properties of 
membranes have been shown to alter the  
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A. 
 
B. 
 
Figure 1.1 Cholesterol and the orientation of cholesterol in the membrane. A. The 
chemical structure of the cholesterol molecule.  B. Depicts the energetically 
favorable placement of cholesterol in the membrane. Cholesterol is oriented 
below the membranes surface with the hydrophobic portion of the molecule 
interacting with the phospholipid tales and the hydrophilic hydroxyl group 
interacting with the phospholipid heads.  
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behavior of a number of integral membrane protein, including ion channels, 
membrane receptors, and enzymes [1].  The broad influence of cholesterol on 
such a large number of cellular processes is why cholesterol homeostasis is so 
important to the cell and so tightly regulated [1].   
1.2 Cholesterol homeostasis  
 Due to cholesterol misregulation leading to such a large number of 
pathological states, cholesterol homeostasis is one of the most highly regulated 
biological processes[4].  Cholesterol can be acquired from food or produced 
within the cells; both acquisitions are tightly regulated in response to the other. In 
addition to this, cholesterol concentration in membranes is very unevenly 
distributed within the cell, leaving sharp gradient between the different 
membranes. While there are many proposed cholesterol transport mechanisms, it 
is still unclear how these gradients are maintained. 
1.2.1 Extracellular cholesterol transport. 
As a hydrophobic molecule, cholesterol must be transported in the blood 
stream by lipoproteins. There are five of these lipoproteins in the human blood 
stream: chylomicrons, very low density lipoproteins (VLDL), low density 
lipoproteins (LDL), intermediate density lipoproteins (IDL), and high density 
lipoproteins (HDL). Of these five proteins, HDL and LDL are predominantly 
responsible for the transport of cholesterol to and from cells in the blood stream. 
LDL is sometimes referred to as “bad” cholesterol as it takes cholesterol from the 
liver to various other tissues. HDL takes cholesterol collected from the bodies’ 
tissues and brings it to the liver. HDL is often referred to as “good” cholesterol 
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because it clears cholesterol from the blood stream as well as retrieving excess 
cholesterol from the cells. 
 Cholesterol levels in the blood stream are maintained by the liver and the 
intestines.  The liver lowers serum cholesterol by removing VLDL and cholesterol 
containing chylomicron, which can then be excreted via bile to feces as well as 
releasing HDL.  The liver can also raise serum cholesterol by synthesizing 
cholesterol and secreting it as LDL.  By these processes, the liver can modulate 
the levels of cholesterol in the blood for cellular uptake [5].   In addition to the 
liver, the intestines can impact cholesterol homeostasis by modulating the levels 
of cholesterol absorption from food into the blood stream [6].   
1.2.2 Regulation of Cholesterol Synthesis 
 In mammalian cells, cholesterol is produced in the ER, and is synthesized 
via a lengthy reaction sequence, requiring 30 enzymatic steps. The rate limiting 
step is the CoA reductase 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMG-
CoAR).  This step has been the target of several cholesterol lowering drugs 
(statins), 
Cholesterol synthesis is regulated by a family of sterol binding proteins, 
sterol regulatory element-binding protein (SREBP).  The most prominent SREBP 
is SREBP2.  When cholesterol levels are normal in the cell, SREBP2 is located in 
the ER in a complex with SREBP2 cleavage-activating protein (SCAP) and Insig-
1. In this form, the complex is inactive. When cholesterol levels decrease, Insig-1 
dissociates from the SREBP2/SCAP complex and is degraded [7] (Fig1.2) .   The 
SREBP2/SCAP complex will then travel to the Golgi apparatus where SCAP will 
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Figure 1.2 Schematic illustration of the transcriptional regulation of cholesterol 
homeostasis. In cases of high cholesterol, the inactive complex of SREBP2, 
SCAP, and Insig-1is located in the ER. When cholesterol levels decrease, Insig-1 
dissociates from the SREBP2/SCAP complex and is degraded.  The 
SREBP2/SCAP complex is transported to the Golgi where SCAP will cleave and 
release part of SREBP2 from the membrane. This fragment diffuses to the nucleus 
of the cell where it acts as a promoter by binding to sterol response element 
(SRE).   
 
Figure taken with permission form Elina Ikonen (2006) Mechanisms for Cellular 
Cholesterol Transport: Defects and Human Disease, Physiological Reviews, Vol. 
86 no. 1237-1261 October 1, 2006 
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cleave and release part of SREBP2 from the membrane. The water-soluble 
fragment will then enter the nucleus, of the cell where it acts as a promoter by 
binding to sterol response element (SRE).  SRE is located in the promoter region 
of numerous genes involved in cholesterol synthesis. [8].  This results in a large 
increase in cholesterol production.      
1.2.3 Cholesterol Uptake  
 Cholesterol, from nutrients, is taken up by the intestines and then 
packaged into lipoproteins for transport in the blood stream.  Cholesterol then 
travels from the intestines to the liver by way of chylomicrons where it is 
repackaged into other lipoproteins for distribution to the cells.  The lipoproteins 
packed in the liver, mainly LDL, can be easily taken up by cells. This process 
involves the LDL particle binding to the LDL receptor (LDLr) via a protein in its 
outer coat called ApoE/ApoB.  The particle and the receptor are then both 
endocytosed through clathrin coated vesicles into acidic endocytic compartments 
[9].  In these vesicles, cholesterol esters are hydrolyzed by an acid lipase. The low 
pH in the early endosome causes the LDLr to dissociate for the LDL particle and 
the receptor is then recycled back to the cell surface [4]. (Fig 1.3)  The remaining 
contents of the LDL particle, primarily cholesterol, moves on to the late 
endosomes where they are distributed to other cellular membranes by a yet 
unclear mechanism. This mechanism is, however, thought to involve two proteins 
NPC1 and NPC2. These proteins are suspected to be involved because 
inactivation of either protein results in Niemann-pick disease type C, the main 
symptom of which is an accumulation of cholesterol in the late endosome.  
 9 
 
 
 
 
 
 
 
 
Figure 1.3 Intracellular cholesterol transport. LDL (yellow circles) carrying 
cholesterol and cholesterol esters bound to LDL receptors (light blue Y-shape). 
Cholesterol molecule are shown in red and the movement of cholesterol is 
depicted by the Gray arrows with the dashed arrows indicating that the 
mechanism by which this transport occurs is poor understood.   
Figure taken with permission form Frederick R. Maxfield1 & Ira Tabas (2005) 
Role of cholesterol and lipid organization in disease, NATURE ,Vol 438 1 
December 2005 
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1.2.4 Cholesterol Efflux 
 Most cells are incapable of degrading cholesterol. Therefore, cells need a 
mechanism by which cholesterol is transported outside of the cell and to the liver 
for reutilization or excretion.  The main carrier of cholesterol back to the liver is 
HDL.  HDL removes cholesterol from cells by passive diffusion of cholesterol 
into the HDL particle. The enzyme lecithin-cholesterol acyltransferase (LCAT) 
has been suggested to aid in this process.  LCAT is located in the surface of lipo-
protein particles mainly those containing HDL, and it has been shown to esterify 
cholesterol.  The then esterified cholesterol will readily transfer to the HDL 
particle [10].  The HDL particle then circulates through the blood stream to the 
liver where it is absorbed. Cholesterol is removed by the scavenger receptor class 
B type1 (SRB1). While the LCAT pathway is the best defined mechanism of 
cholesterol removal, several other methods have been suggested, but poorly 
defined. It has also been shown that cholesterol can be removed in the absence of 
LCAT, so other methods are likely to emerge. [4]. 
1.2.5 Cholesterol Esterification and Storage 
 Cholesterol can be stored for extended periods of time in what are referred 
to as liquid droplets. They are large monolayer phospholipid vesicles with a 
neutral, lipid rich core consisting of steryl esters and triglycerides. These droplets 
are used for the storage of lipids, predominantly cholesterol and acylglycerols. 
The outer lipid monolayer has been shown to contain proteins that regulate lipid 
droplet dynamics and lipid metabolism.  The net trafficking of cholesterol into or 
out of lipid droplets is linked to cellular cholesterol levels. Cholesterol is 
continually trafficked both in and out of lipid droplet, regardless of external cues, 
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although these cues do result in changes in the cholesterol balance. It is as of yet 
unclear by what mechanism cholesterol esters are trafficked into the lipid droplet. 
It has been shown that the transfer does not require energy input [11]. Some have 
suggested that the droplets may remain connected to the ER allowing for the 
simple diffusion of cholesterol esters. This is supported by the fact that the lipid 
droplets are likely derived from the ER. What, if anything, regulates this process 
remains very poorly understood.  
The esterification of cholesterol for trafficking into lipid droplets involves 
the 3’-OH being fatty acylated to from a cholesterol ester. This process is 
accomplished via the enzyme acyl-CoA:cholesterol acyltransferase (ACAT). 
ACAT has two homologs expressed in most mammals (ACAT1 and ACAT2). 
They are both integral ER proteins, but are differentially expressed in various cell 
types. The degradation of cholesterol esters for trafficking out of lipid droplets 
involves the enzyme neutral cholesterol ester hydrololase (nCEH). This enzyme is 
located in the coat of the lipid droplets. As with ACAT, there are several 
homologous nCEHs in different cell types. The mechanism by which cholesterol 
esters move in, or cholesterol moves out, of the lipid droplets is very poorly 
understood.  
1.2.6 Cellular Cholesterol Trafficking 
 Cholesterol is critical to many cellular functions, but it is far from evenly 
distributed throughout the organelles. Cholesterol is produced in the ER, but the 
majority of it resides in the plasma membrane. This requires cholesterol to be 
actively transported up a very steep gradient. In case of excess buildup of 
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cholesterol on the plasma membrane, cholesterol is returned to the ER of 
esterification and storage in lipid droplets. These two pathways appear to be 
independent due to the fact that they can be stimulated separately [12]. 
Maintaining this specific distribution of cholesterol is critical to cellular viability. 
As such, there are numerous mechanisms by which cholesterol can be distributed 
to different parts of the cell, through either vesicle or non-vesicle transport.  
1.2.6.1 Non-Vesicle Transport of Cholesterol  
Due to the hydrophobic nature of cholesterol, all non-vesicle transport 
requires a carrier protein with a hydrophobic pocket to solubilize the cholesterol 
molecule. While the exact identity of cholesterol carrier proteins remains elusive, 
several proteins have been implicated in cholesterol transport. These proteins 
include sterol carrier protein 2(SCP-2), caveolin, theoxysterol-binding protein-
related protein (ORP) family, and steroidogenic acute regulatory (StAR) protein 
related lipid transport domain [4]. 
 SCP-2 is a small soluble protein (13.3 Kd) formed by the cleavage of a 
larger protein SCP-X.  SCP-2 has been shown to bind cholesterol, as well as other 
lipids.   SCP-2 has also been shown to transport cholesterol between artificial 
membranes [13].   When SCP-2 is inhibited cellular distribution of cholesterol is 
disturbed [14].  In several tissue types, SCP-X remains almost completely 
involved with intake and is almost non-detectable in the cytosol [11].   While 
SCP-2 likely plays a role in cholesterol transport, the exact role is yet to be 
determined, and it is clearly not the sole mechanism of cholesterol transport.  
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  StAR is responsible for shuttling cholesterol between the outer and inner 
membranes of mitochondria. StAR has been shown to bind cholesterol at a 1:1 
ratio, and when knocked down, the transfer of cholesterol from the inner to the 
outer membrane is abolished [11]. Little else is known about the StAR proteins 
exact mechanism or what other proteins may be involved. 
ORPs are a family of lipid binding proteins, many of which have been 
shown to bind cholesterol or cholesterol derivatives. Humans have at least 12 
different ORPs, which are thought to play a role in regulation of lipid distribution 
and metabolism, cell signaling, and vesicular transport. It is not as of yet clear if 
ORPs directly play a role in cholesterol transfer, but when knocked down in yeast, 
they have been shown to greatly reduce the speed of cholesterol transfer from the 
ER to the plasma membrane.  
Caveolin is a common membrane protein that oligomerizes on the surface 
of the membrane to create caveolae, cholesterol, and sphingolipid-rich 
invaginations. Whether or not caveolin is involved in cholesterol transport, 
though, is unclear. It has been shown to bind cholesterol, but this may just be for 
the purpose of organizing it on the membrane [15]. More study is needed to 
determine the mechanism by which it traffics cholesterol throughout the cell. 
1.2.6.2 Vesicle Transport of Cholesterol 
 In addition to all of the methods listed above, cholesterol can also move as 
part of the membrane in a small vesicle. These vesicles are thought to travel 
between the ER and the plasma membrane in both directions. (Fig 1.3)  When 
coming from the ER to the plasma membrane, cholesterol mostly goes through 
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the Golgi apparatus in a manner similar to protein secretion. This pathway is 
thought to be minor due to the fact that Golgi disassembly only reduces 
cholesterol transport to the plasma membrane by 20%, whereas protein secretion 
was reduced by 90% in the same cells. It has been suggested that vesicle transport 
could bypass the Golgi, but little evidence of this has been shown.  
 Cholesterol has been shown to return from the plasma membrane to the 
ER for esterification though the exact mechanism remains unclear. Loading cells 
with cholesterol causes vesicles to break off the plasma membrane in an ATP 
independent manner, though ATP is required for the delivery of these vesicles to 
the late endosome and lysosomes. This cholesterol is then trafficked to the ER in 
the same fashion as cholesterol taken from the media. This is supported by the 
fact that NCP-1 and NCP-2 deficient cells show significantly reduced transport of 
cholesterol for esterification. In addition to this path, retrograde transport of 
cholesterol through the Golgi has been implicated, but is at best a minor pathway.  
1.3 Cholesterol Accessibility 
Cholesterol modulates important membrane properties including 
permeability, fluidity, thickness, and domain formation. The cholesterol-
dependent association of certain proteins and peptides with membranes has been 
often associated with the effect of cholesterol on one or more of these membrane 
physical properties. More recently, studies with molecules that directly interact 
with cholesterol, such as cyclic sugar polymers [e.g., cyclodextrins, 16], enzymes 
[e.g., cholesterol-oxidase, 17], and bacterial toxins [e.g., PFO, 18-21] have shown 
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that the accessibility of cholesterol at the surface of the membrane also plays a 
critical role in cell biology. 
Cholesterol is insoluble in aqueous solutions, but it is readily soluble in 
phospholipid bilayers. The solubility limit of cholesterol in lipid bilayers is 
dictated by the nature of the phospholipids [acyl chain length and saturation, and 
head group size, 22]. If the concentration of cholesterol in a bilayer increases to 
levels above its solubility limit, cholesterol aggregates would form crystals and 
precipitate out into the aqueous solution [23-25].  Given its hydrophobic nature 
and how it situates itself in the membrane, at low concentrations, the interaction 
of cholesterol with other membrane components (lipids, proteins, etc.) reduces the 
ability of cholesterol to interact with water-soluble molecules at the membrane 
surface. In other words, when present in low amounts, cholesterol is not 
accessible to interact with water-soluble molecules such as PFO or cyclodextrins. 
As the concentration of cholesterol increases, the accessibility remains low until a 
saturation point is reached. The concentration of cholesterol at the saturation point 
will depend on the phospholipid or phospholipid mixture present in the membrane 
(Fig. 1.4A). At this point, a small increase in the sterol concentration causes a 
sharp increase in the ability of water-soluble molecules to interact with 
cholesterol [16, 17, 26]. Different models have been proposed to explain changes 
on cholesterol accessibility at the membrane surface: the cholesterol:phospholipid 
complex model and the umbrella model [27,28]. Despite their thermodynamic or 
steric basis, the models are not mutually exclusive [29, 30]. Recent molecular 
dynamics simulations of simple membrane models [31] suggested that cholesterol 
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accessibility is related to the overall cholesterol depth within the membrane 
bilayer and not to the appearance of a new pool of cholesterol molecules 
(sometimes referred as free cholesterol or active cholesterol). In favor of clarity in 
this chapter, I will refer to the effect that causes an increase in the interaction of 
cholesterol with water-soluble molecules, as an increase in cholesterol 
accessibility at the membrane surface (Fig. 1.4). 
1.3.1 Role of Cholesterol Accessibility in Cholesterol Homeostasis.  
As I have illustrated in the preceding section, cholesterol homeostasis is 
critical to cell viability, but the mechanisms by which it is controlled are not well 
understood. Recently, it has been proposed that cholesterol accessibility plays an 
important role in maintaining of the cholesterol gradients that exist between the 
organelles within the cell [21,32].  While it has been well documented that the 
plasma membrane (30-40 mol % cholesterol) has significantly more cholesterol 
than that of the ER (2-8 mol % cholesterol),it has been shown that the cholesterol 
accessibility of the two membranes is very similar[33,21]. This is possible 
because of the difference in the other membrane constituents that compose these 
membranes, and how strongly they interact with cholesterol. For example, 
sphingolipids interact strongly with cholesterol in the plasma membrane, and as a 
result, when this lipid is destroyed by sphingomyelinase, the cholesterol 
accessibility of the membrane increases greatly. This results in 15-30% of the 
plasma membrane cholesterol being transported back to the ER for esterification 
[34].  This action is believed to be the cell readjusting to the proper cholesterol 
accessibility. This indicates that imbalance of cholesterol accessibility 
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Figure 1.4 Cholesterol accessibility changes at the membrane surface as a 
function of the lipid composition. A. When interactions with other membranes 
components saturate the accessibility of cholesterol increases at the membrane 
surface. B At constant cholesterol concentration, an increase in the number of 
double bonds on the acyl chains of the phospholipids increases cholesterol 
accessibility. C. At constant cholesterol concentration, an increase in the 
concentration of phospholipids with smaller head groups increases cholesterol 
accessibility. The red lines depict a hypothetical increase on cholesterol 
accessibility. The actual change on cholesterol accessibility for each schematic 
graph may differ from a simple linear response. Some cholesterol molecules are 
colored red to visualize the increase on accessibility but they are indistinguishable 
from other cholesterol molecules in the membrane 
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triggers the trafficking of cholesterol from the plasma membrane to the ER. While 
the mechanism by which many of the sterol transport proteins work is still a 
mystery, they are mostly soluble proteins, and cholesterol accessibility seems very 
likely to play a factor in their binding to cholesterol. Cholesterol accessibility 
merely provides a simple means of maintaining the stark cholesterol gradient 
between the ER and the plasma membrane.  
   The activation of the SREBP2/SCAP complex has long been shown to be 
controled by the cholesterol levels in the ER (Fig. 1.2). The complex is retained in 
high cholesterol levels and released when cholesterol is low. Recent work has 
correlated this transition to the binding threshold of proteins known to have 
binding threshold linked to cholesterol accessibility (PFO, cyclodextrin) [21]. 
This would indicate that accessible cholesterol is what keeps INSIG-1 from being 
degraded in the SREBP2/SCAP complex in the ER. The result of this is a link 
between cholesterol accessibility and the regulation of cholesterol production. 
1.3.2 Need for better cholesterol probes to study cholesterol in the cell 
The complexity of the mechanism by which cholesterol homeostasis is 
regulated speaks to its supreme importance to the viability of all mammalian cells.  
The study of cholesterol homeostasis has been hindered by the redundancy of the 
mechanisms involved.  Many different processes seem to act in unison to 
maintain proper cholesterol levels. We have reached the limit of what can be 
achieved through the knock down of single genes. In such a complicated system, 
better ways to track cholesterol and cholesterol accessibility are required to 
further define the system and all the players involved. 
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1.4 Current cholesterol probes 
A diverse array of probes has been put forth as detection methods for 
cholesterol in the membrane.  Among them, is everything from small molecules, 
like filipin, to whole proteins, like cholesterol dependent cytolysins (CDC) or 
cholesterol oxidases.  In addition to standard probes, a large number of 
fluorescent cholesterol analogs have been created for the purpose of tracking 
cholesterol movement in the membrane.     
 Filipin is a polyene antibiotic that exhibits potent antifungal activity. 
Filipin is also highly fluorescent and binds specifically to cholesterol, presumably 
to the hydroxyl group of the cholesterol molecule [35].    While widely used, 
filipin staining tends to be somewhat ubiquitous at high concentration and uneven 
and prone to artifacts at lower concentration [36].  In addition, while filipin 
penetrates membranes, which can be useful, it also significantly disrupts them, 
which is very undesirable.     
 Cholesterol oxidase is an enzyme that converts cholesterol and oxygen 
into 4-cholesten-3-one and hydrogen peroxide.  Hydrogen peroxide can then be 
detected by an oxidative coupling reaction in the presence of peroxidase that 
subsequently forms a chromogen or fluorophore, which can then be easily 
detected. Cholesterol oxidase activity has been shown to be dictated by 
cholesterol accessibility, because the cholesterol molecule has to at least partially 
leave the membrane to enter the active site of the enzyme. The main problem with 
cholesterol oxidase is that it oxidizes cholesterol by converting the sterol to a 
steroid and drastically changing its properties, thus causing it to no longer 
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condense or organize membranes in the same fashion. This can be very 
problematic, especially to longer term experiments.    
 Cholesterol analogs have proven very useful in tracking the movement of 
cholesterol. There are two kind of fluorescent cholesterol analogs; those that are 
intrinsically fluorescent and those that have a linked fluorophore.  Intrinsically 
fluorescent cholesterol analogs, generally, more resemble cholesterol, but have 
low quantum yield and are prone to rapid photobleaching.  As a result, larger 
amount of cholesterol analogs must be added to a cell that already contains 
cholesterol. This results in overloading of the cell.  Cholesterol analogs with 
linked fluorophores are more photo-stable, allowing for lower density loading, but 
have issues with distribution and trafficking [37].     
Cholesterol dependent cytolysins (CDC) are a family of pore forming 
toxins that bind to cholesterol containing membranes. They have primarily been 
used to detect high level of cholesterol, those over 30 mol%.  This high 
cholesterol requirement led to CDCs being originally put forth as a method to 
detect lipid rafts.  CDCs have also been used as an assay for the detection of high 
cholesterol disease states such as Niemann-Pick disease.   More recently, the high 
binding threshold of CDCs was suggested to be the binding of accessible 
cholesterol by the protein.  CDCs are somewhat limited by their high binding 
threshold, which makes them unsuitable for use on cholesterol poor membranes. 
[36].   While the previously discussed probes are capable of detecting cholesterol 
concentration, only CDC’s are capable of detecting cholesterol accessibility 
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effectively.  All currently available probes are imperfect and better probes are 
required to further the understanding of the role cholesterol plays in the cell. 
1.5 Perfringolysin O  
Perfringolysin O (PFO) is the prototypical example of a growing family of 
bacterial pore-forming toxins known as CDC [38, 39, 40]. CDCs are secreted by 
Gram-positive bacteria including Bacillus, Listeria, Lysinibacillus, Paenibacillus, 
Brevibacillus, Streptococcus, Clostridium, Gardnerella, Arcanobacterium, and 
Lactobacillus [see 39, 41, 42]. There are 30 members of the CDC family reported 
for Gram-positive bacteria and, surprisingly, two CDC-coding DNA sequences 
have been found in the Gram-negative Desulfobulbus propionicus and  
Enterobacter lignolyticus. However, in contrast with the Gram-positive bacteria 
that produce CDCs, the Gram-negative ones have not been shown to inhabit 
humans, or indeed animals, of any kind [43]. Despite their extremely diverse 
lineage, the majority of CDCs show an amino acid sequence identity greater than 
39% when compared to PFO (figure1.5). The C-terminus (domain 4 or D4) of 
PFO is responsible for membrane binding and is the domain with the highest 
percentage of amino acid identity when sequences are compared with other CDC 
members. 
 
Most CDCs possess a cleavable signal sequence, which targets the toxin 
for secretion to the extracellular medium. The secreted water-soluble toxins 
diffuse until encountering their target, a cholesterol-containing mammalian cell 
membrane (Fig. 1.6, step I). An exception to the cholesterol requirement, 
for targeting, was found for intermedilysin, which uses the human receptor CD59 
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Figure 1.5. Analysis of the primary structure for the CDCs reveals a high degree of identity and similarity among them. Only 
the sequence for the conserved core of the CDCs was used for the analysis (corresponding to PFO amino acids 38–500). If 
more than one sequence was available for individual species, only one was used in the analysis. Sequence relationships were 
calculated using the MatGat 2.02 alignment program using the BLOSUM 62 matrix and open and extension gap penalties of 
12 and 1, respectively (Campanella et al., 2003). The identity scores occupy the upper triangle (in bold) with scores higher than 
70% shaded in dark gray, and those at 50–70% in light gray. Similarity scores in the lower triangle were shaded in dark gray if 
higher than 80% and in light gray if between 70 and 80%
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for membrane targeting [44].  However, this toxin still requires cholesterol to 
insert into the membrane and form a transmembrane pore [45]. After binding, 
CDC monomers diffuse across the surface of the membrane and interact 
reversibly with other monomers until formation of a stable dimer [Fig. 1.6, step II, 
46, 47]. These initial dimers grow by the incorporation of additional monomers 
into a large ring shaped complex (known as the pre-pore complex, [Fig. 1.6, step 
III, 48]. Each of these complexes contains 30-50 monomers, and upon insertion 
into the membrane, form large -barrel pores [up to 250-300 Å in diameter, Fig. 
1.6 step IV, 49, 50, 51].  
PFO is secreted by Clostridium perfringens as a 52.6 kDa protein, and the 
crystal structure of the water-soluble monomer revealed four distinct domains 
[Fig. 1.7A, 52]. The overall three dimensional structure observed for PFO is 
conserved for all other CDCs whose high resolution structures have been solved 
[53-55]. Domain 1 (D1) consists of the top portion of the elongated molecule. D1 
is the only domain that does not undergo large structural rearrangements during 
pore formation. Domain 2 (D2) adopts mostly a -strand secondary structure that 
collapses vertically during pore-formation to allow the insertion of the -hairpins 
that form the transmembrane -barrel [49, 56-58]. Domain 3 (D3) contains both 
the -sheet involved in the oligomerization of the toxin and the six short -helixes 
that unfurl into two amphipathic -hairpins to form the -barrel [50, 51, 59].  D4 
consists of a -sandwich and contains a conserved Trp rich loop, as well as, three 
other conserved loops at the distal tip (Fig. 1.7B and C). D4 is responsible for  
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Figure. 1.6 Cartoon representation of the different steps/intermediates identified 
for the PFO mechanism of pore formation. A water-soluble monomer is secreted 
by the bacterium and binds to the target membrane via D4 (step I). Membrane-
bound monomers diffuse across the membrane surface interacting transiently until 
they form a stable dimer (step II). The initial dimer starts growing with the 
addition of other monomers until completion of a circular ring or pre-pore 
complex (step III). In the last step, each monomer inserts two amphipathic 
transmembrane hairpins into the bilayer aided by the vertical collapse of D2 
forming a large β barrel pore (step IV). Domains are numbered and color coded as 
follows: D1 (green), D2 (yellow), D3 (red), and D4 (blue). Only a few PFO 
monomers are shown in the side view at the bottom to simplify the figure. On the 
top is a schematic top view for each step of the pore formation mechanism shown 
below. The membrane bilayer is depicted by a gray rectangle. 
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Figure 1.7 Three dimensional structure of PFO showing the location of important 
elements that modulate cholesterol interaction. A. Ribbon representation of the 
water-soluble PFO monomer with domains colored as indicated in Fig. 1.5. Also 
in color are three key residues that influence cholesterol interaction T490, L491, 
R468 (Red), and the Trp rich loop (TRL, orange). B. A view of the tip of D4 from 
the bottom showing the exposed surface of the Trp rich loop residues (orange), 
the three small loops (green), and the residues indicated in A (red). C. The ribbon 
rendering of the same bottom view of D4 shown in B. PFO (1PFO) structure 
representation was rendered using PyMol (DeLano Scientific LLC) 
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cholesterol recognition and the initial binding of the toxin to the membrane [26, 
60]. 
1.5.1 Binding and pore formation mechanism 
One of the unique features of the mammalian cell membrane is the 
presence of cholesterol. C. perfringens and other pathogens have exploited this 
property of mammalian membranes to target their CDCs without compromising 
the integrity of their own membranes.  The cholesterol recognition of PFO is via 
D4. The full binding mechanism will be discussed in detail in section 1.5.3  
1.5.2 Oligomerization on the Membranes Surface 
 Upon binding to a cholesterol containing membrane, PFO diffuses across 
the surface of the lipid bilayer and oligomerizes into a large ring shaped complex 
(Fig. 1.6). This complex contains 35-50 individual PFO monomers (~250-300 Å 
inner diameter) and it is referred to as the pre-pore complex [48, 49, 61]. 
Transition of the pre-pore complex to the final membrane-inserted complex 
occurs by the insertion of numerous -hairpins (two per monomer) that perforate 
the membrane forming a large transmembrane -barrel [50]. The conformation of 
the individual PFO monomers in the pre-pore complex is not vastly changed from 
that of their water-soluble form. There are subtle structural changes that are 
triggered by membrane binding and oligomerization of the protein that allow for 
proper alignment of the monomers and the overall geometry of the pore [59]. 
Formation of complete rings at the surface of the membrane seems to be regulated 
by the relatively slow formation of an initial CDC dimer [46, 47]. 
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1.5.2.1 Nucleation of the Pre-pore Complex 
Oligomerization of the CDCs is triggered by membrane binding and 
interaction with cholesterol (or exceptionally by interaction with a protein 
receptor for intermedilysin). Cholesterol binding is sufficient to trigger the 
conformational changes that unblock the hidden oligomerization interface in the 
water-soluble monomer [59, 62]. Blockage of the oligomerization interface in the 
monomer prevents premature oligomerization of the toxin in solution. This 
regulatory mechanism can be overridden if the monomers are present at high 
concentration in solution [e.g., for pneumolysin, 63, 64], but oligomerization is 
rare at physiological concentrations (i.e, nM range or lower). 
The most significant of the conformational changes that follows 
membrane binding involves the exposure of the core -sheet that comprises a 
larger part of D3. A short -strand (β5) separates from the core -sheet in D3 and 
exposes β4 for its interaction with the always-exposed β1 strand of another PFO 
molecule, promoting oligomerization [59, 65]. This conformational change is 
thought to be facilitated by a pair of Gly residues, G324 and G325, located in the 
loop between β4 and β5. These Gly residues are highly conserved, and act as a 
hinge between the two β-strands [66]. In addition to the separation of β5 from β4, 
it has been suggested that there is a disruption of the D2 and D3 interface. This 
disruption is thought to be caused by the rotation of D4, which breaks the weak 
interactions between D2 and D3. These conformational changes cause the rotation 
of D3 away from D1, and ultimately the unfurling of the transmembrane hairpins 
[47, 67]. 
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Hotze et. al. have recently suggested that the initial interaction between 
two membrane-bound PFO monomers is weak and transient. This interaction is 
rarely of sufficient length to allow for the transition to a stable dimer with β1 and 
β4 strands properly aligned. However, if the transition occurs, addition of further 
PFO monomers to the complex becomes favorable and oligomerization ensues. 
Therefore, formation of a stable initial dimer constitutes the rate limiting step in 
oligomerization that diminishes the formation of uncompleted rings on the 
membrane surface [Fig. 1.6, step II, 47]. While it has been originally proposed 
that the separation of β5 from β4 happens upon membrane binding [66], it is still 
unclear whether these structural changes are caused by toxin binding or as a 
consequence of monomer-monomer oligomerization. 
1.5.2.2 Alignment of Core β-sheets 
Addition of monomers to the growing oligomer requires the proper 
alignment of the core -strands of the newly added PFO monomer with a  strand 
at the edge of the oligomer. Formation of hydrogen bonds between adjacent β-
strands is energetically favorable, but non-specific in nature. If the alignment is 
incorrect, proper growing of the oligomer would not be possible. It is critical to 
regulate the alignment of neighbor β-strands to prevent the formation of truncated 
pre-pore complexes. The correct alignment of adjacent -strands among 
individual PFO monomers is dictated by -stacking interactions between aromatic 
residues located in 1 (Y181) and 4 (F318) [66]. Modifications on either of 
these residues have proven to be extremely deleterious to the ability of PFO to 
form pores.  Interestingly, despite being a critical interaction, it appears that only 
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Y181 is completely conserved among the CDCs. A few CDC family members do 
not contain an aromatic residue in the corresponding location of F318 in PFO, 
suggesting that proper alignment of adjacent -strands may follow another 
regulatory mechanism for these members [i.e., lectinolysin, intermedilysin, 
vaginolysin, pneumolysin, mitilysin, pseudoneumolysin, and the two newly 
identified members, see 39, 41, 42]. 
1.5.3 Mechanism of Pore Formation  
  The last step in the cytolytic mechanism of PFO is the formation of the 
transmembrane pore. The pre-pore complex transitions into a membrane-inserted 
complex forming a large transmembrane β-barrel (Fig. 1.6, step IV). This 
transition involves the unfurling of six short α-helixes located in D3 down to two 
amphipathic β-hairpins, and the collapse of D2 to bring down the β-hairpins so 
they can span the hydrophobic core of the membrane. Large secondary and 
tertiary structural changes are required to coordinate the insertion of more than 
140 individual β-strands and the removal of thousands of lipid molecules to form 
a β-barrel pore. The use of two β-hairpins per monomer to create a 
transmembrane -barrel was first described for PFO [50, 68], and it is likely that 
this mechanism is also employed by other important pore-forming proteins like 
the membrane attack complex/perforin (MACPF) proteins [69-71]. 
A key step in the pore formation mechanism of the CDCs is the unfurling 
of six short α-helixes in D3 to form two extended amphipathic β-hairpins [50, 62, 
72]. These conformational changes are necessary to minimize the exposure of 
hydrophobic residues in the water-soluble form of the PFO monomer [50, 73]. 
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After insertion, the hydrophobic side of the amphipathic hairpin faces the non-
polar lipid core, and the hydrophilic side faces the aqueous pore [Fig. 1.6, 50, 51]. 
The exact molecular mechanism for the pre-pore to pore conversion remains 
unknown, but thermal energy plays a key factor, since at low temperatures (e.g., 4 
°C) the PFO oligomer remains locked at the pre-pore complex state [48, 74].   
Sato et al have recently shown that in the pre-pore complex the -strands 
that form the transmembrane pore are flexible and mobile [72]. These 
transmembrane -hairpins are located high above the membrane in the pre-pore 
complex [56, 58] and are able to extend and test hydrogen bonding arrangements, 
but they do not fully form a -barrel structure [72, 74]. This partially unfolded 
state of the -hairpins is thought to represent an intermediate step in pre-pore to 
membrane-inserted complex transition for PFO [72]. The partial alignment of the 
-hairpins in the pre-pore complex may constitute a kinetic barrier that deters the 
insertion of incomplete rings favoring the formation of complete pre-pore 
complexes. 
The unfurling of the two α-helical bundles into two -hairpins is favored 
by the formation of multiple hydrogen bonds, both between hairpins within a PFO 
monomer and between hairpins on adjacent monomers (Fig. 1.8). Crosslinking 
experiments revealed that the -hairpins in the inserted -barrel adopt a ~20 
degree angle to the plane of the membrane, and the adjacent inter-monomer 
strands align themselves with a shift of two amino acids [Fig. 1.6, 72]. As 
mentioned above, PFO oligomerization is aided by the proper alignment of - 
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Figure 1.8 A schematic view that depicts the position and orientation of the 
transmembrane hairpins (TMH1 and TMH2) of PFO in the membrane-inserted 
complex as determined by Sato et al (2013). The tilted membrane and the 
rectangle representing the rest of the PFO molecule are depicted in gray and blue, 
respectively. The amino acids that compose the D3 β sheet and the 
transmembrane hairpins are depicted by their single letter code and color-coded 
according to conservation in the CDC family. Amino acids conserved in more 
than 90% of the 28 CDC members are shown in red, in orange if conservation was 
higher than 70% but lower than 90%, and in black if not highly conserved. 
Highlighted in green are the aromatic amino acids that are thought to be involved 
in π-stacking interaction that stabilize PFO pre-pore confirmation and help to 
align individual PFO monomers for pore formation (see text for details) 
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strands from adjacent monomers via -stacking interaction between the 
completely conserved Y181 and the highly conserved F318. Inspection of the 
extended hairpins in the -barrel conformation (Fig. 1.8) revealed another 
potential -stacking interaction that may act to stabilize the hairpins in their 
extended conformation. These are the completely conserved F211 in the 
transmembrane hairpin 1 (TMH1) and highly conserved F294 (present in all but 
vaginolysin, lectinolysin, and intermedilysin of the 30 members) in the 
transmembrane hairpin 2 (TMH2). Interestingly, the F211C modification 
decreased the hemolytic activity of PFO [51] and the PFO derivative containing 
the F294C modification could not be stably produced [50]. 
The vertical collapse of D2 to bring D3 closer to the surface of the 
membrane is another important step in pore formation [56, 57]. In the pre-pore 
complex, PFO is positioned perpendicular to the membrane leaving D3 about 40 
Å above the membrane surface [56, 58]. In this position, the -strands that form 
the pore would barely reach the membrane surface and could not penetrate the 
membrane. The required vertical collapse of D2 would drop D3 to the membrane 
surface and allow the -hairpins to punch through the membrane and form a 
-barrel. Unfortunately, little is known about the mechanism of the 
transmembrane -barrel insertion. 
Formation of a pre-pore complex and formation of hydrogen-bonds 
between adjacent -strands helps the toxin to overcome the energetic barrier of 
inserting non-hydrogen bonded -hairpins [39]. The insertion of incomplete rings 
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may also occur, especially when free monomers are no longer available to 
complete the circular complex. Trapped metastable arc-like structures may form a 
pore by themselves, but the formation of a lipid edge at one side of the pore is not 
energetically favored, and the arcs would have a tendency to associate with other 
arcs or any proximal complete rings [75-77]. 
One of the most intriguing aspects of the CDCs cytolytic mechanism is 
what happens to the lipids that are displaced to form the pore. The insertion of the 
β-barrel requires the displacement of more than 1000 lipid molecules from the 
membrane [68]. It is not clear how such a large amount of molecules are removed 
from the center of the pre-pore complex, but the hydrophilic nature of the inner 
portion of PFO the -barrel could aid in this process. 
1.5.4 Domain 4 and cholesterol recognition and binding 
Binding of PFO and other CDCs requires high levels of cholesterol in 
model membranes prepared with phosphatidylcholine [78-80]. Based on the 
requirement of high cholesterol levels, targeting of PFO to cholesterol rich 
domains or “lipid rafts” has been suggested. However, it has become clear that 
exposure of cholesterol at the membrane surface is a key factor to trigger PFO 
binding, and “lipid rafts” may not be necessary for toxin binding [18-21, 31, 62]. 
The localization of PFO oligomers on the surface of the membrane may change 
from the original binding site after insertion of the -barrel [81, 82].  
The binding of PFO to cholesterol containing membranes is modulated by 
amino acids located in the loops that connect the -strands at the bottom of D4 
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[Fig. 1.7C, 20, 83, 84-87], however the precise molecular mechanism of CDC-
cholesterol interaction remains poorly understood. 
1.5.4.1 Cholesterol Recognition  
The first step in the binding of a water-soluble CDC to the membrane 
involves the formation of a non-specific collisional complex between a monomer 
and the lipid bilayer. This step is diffusional and electrostatic interactions may 
play an important role [e.g., introduction or elimination of negative charges alters 
binding, 83, 86]. While on the membrane surface, insertion of non-polar and 
aromatic amino acids, and/or specific interactions with membrane lipids, may 
anchor the protein to the membrane [88]. However, non-polar amino acids are 
rarely exposed on the surface of water-soluble proteins, and therefore 
conformational changes are often required to expose these residues to the 
hydrophobic core of the membrane bilayer. As a result, multiple conformational 
changes are triggered during the transition of PFO from a water-soluble monomer 
to a membrane-inserted oligomer. 
In model membranes prepared exclusively with phosphatidylcholine, > 30 
mol% cholesterol is required to trigger binding of PFO [26, 80], streptolysin O 
[79], lysteriolysin O [89], or tetanolysin [78], but the amount of cholesterol 
needed does vary depending on membrane phospholipid composition. The 
“cholesterol threshold” can be reduced by the presence of double bonds in the 
acyl chains of the phospholipids or by the presence of phospholipids with smaller 
head groups [18, 19, 90]. Modifications to the phospholipids that form the 
membrane can alter the ability of PFO to detect cholesterol at the surface of the 
membrane [20]. Despite their influence on membrane binding, the presence of 
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phospholipids is not required, since cholesterol alone (in the absence of any other 
lipid) is sufficient to trigger PFO oligomerization and formation of ring-like 
complexes [62 and references therein]. Accessibility of cholesterol at the 
membrane surface seems to be the key to trigger the binding of PFO to 
membranes [19-21, 31]. 
1.5.4.2 Domain 4 and the Conserved Loops 
PFO D4 consists of two four-stranded -sheets located at the C-terminus 
of the protein (Fig. 1.9). There are four loops that interconnect the eight β-strands 
at the distal tip of the toxin, three short loops (L1, L2, and L3) and a longer Trp 
rich loop (also known as the conserved undecapeptide). These loops insert into 
the membrane upon binding and are presumably responsible for the interaction of 
the toxin with cholesterol [60, 83, 85]. Two of these loops (L2 and L3, Fig. 1.7C) 
connect β-strands from opposite β-sheets, while L1 and the Trp rich loop connect 
β-strands from the same β-sheet. L1 and the Trp rich loop are parallel to each 
other and abutted perpendicularly by L2 forming a pocket in the bottom of the 
protein. The loops that form the pocket are the most conserved segments in D4, 
and modifications to any of these loops affects the cholesterol binding properties 
of PFO [20, 85, 86, see below, 91]. The remaining L3 is far less conserved and 
distant from the pocket formed by the other three loops. 
The Trp rich loop is the longest of the D4 loops, containing 11 residues (E 
C T G L A W E W W R). It is a signature feature of the CDCs and is highly 
conserved among species. The three-dimensional structure of this loop seems to 
be more variable [52-55], but this may simply reflect its flexibility [53]. Initially,  
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Figure 1.9 The three dimensional structure of D4 is highly conserved in the CDC 
family. (A) Comparison of D4 from three CDC homologs highlights the 
conserved architecture of this C-terminal domain. A cartoon, upper left, clarifies 
the threading of 2 β-sheets and loops in the β-sandwich and indicates the spatial 
organization of the undecapeptide, L1, and L2. The α-backbone for the D4 
domains of PFO, ILY, and ALO were aligned using PyMol (DeLano 
Scientific LLC; available at www.pymol.org). (B) Alignment of the sequence for 
the 28 CDC family members reveals substantial conservation in loops L1, L2 and 
the undecapeptide. While integrity of the undecapeptide was long recognized for 
being critical to the cholesterol-dependent activity of these toxins, other loops are 
also important. Residues conserved in all sequences are shaded in black, and 
highly conserved residues are shaded in gray. 
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the Trp rich loop was thought to be responsible for cholesterol recognition and 
binding, and this idea was supported by several studies showing that 
modifications in it greatly decreased the pore-forming activity of the protein [91-
97]. However, recent studies showed that the other loops in D4 are also 
responsible for cholesterol recognition [85]. The Trp rich loop has now been 
suggested to play a role in both the pre-pore to pore transition [83] and the 
coupling of monomer binding with initiation of the pre-pore assembly [87]. Dowd 
and colleagues recently showed that modification of a charged amino acid in the 
Trp rich loop (Arg 468, Fig. 1.7B) resulted in complete elimination of the pore-
forming activity of PFO and had a significant effect on the membrane binding of 
the toxin [87, 91]. The R468A PFO derivative was not able to oligomerize after 
membrane binding, suggesting that this modification disrupts the previously 
reported allosteric coupling between D4 and D3 [26]. Despite the novel functions 
assigned to the Trp rich loop, its role in binding cannot be neglected since many 
modifications to this segment have been shown to have a significant effect in 
toxin-membrane interaction [91]. 
Unlike the flexible Trp rich loop, the three-dimensional structure of the 
other three short loops is more conserved. The L3 is located on the far edge of D4, 
away from a pocket formed by the Trp rich loop, L1, and L2 (Fig. 1.7C). 
Modifications introduced into L3 have been shown to have either a negligible 
effect on cholesterol interaction, or to decrease the amount of cholesterol required 
for binding [85, 86]. For example, the elimination of the charge of D434 in L3 
increases the amount of protein able to bind to a given membrane. These results 
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suggest that L3 plays a limited role in cholesterol recognition, and its effect on 
binding may be related to nonspecific interactions with the membrane that 
stabilize the bound monomer at lower cholesterol levels. 
1.5.4.3 Proposed Cholesterol Recognition Motif 
PFO contains a proposed cholesterol recognition motif composed of only 
two adjacent amino acids in L1, T490 and L491 (Fig 1.9) [85]. These amino acids 
are completely conserved throughout all reported CDCs, and modifications to 
them greatly affect the binding of the protein to both cell and model membranes 
[85] . These data suggest a prominent role for these two amino acids in 
cholesterol recognition, however, other well conserved amino acids in that region 
have not been analyzed yet (e.g., H398, Y402 and A404). Moreover, no direct 
interaction between cholesterol and these two residues has been shown so far. The 
fact that both amino acids must be mutated to eliminate binding in a motif 
containing only two amino acids, coupled with the fact that there are many 
additional conserved amino acids in the vicinity, suggest that other amino acids 
may also play a role in cholesterol recognition and form part of the cholesterol 
binding site. Further studies are required in this area. 
1.5.4.4 The Effect of Cholesterol Accessibility on PFO Binding 
 At this time, it is more or less accepted that cholesterol accessibility plays 
a pivotal role in the binding of PFO.  The evidence for this is the high cholesterol 
bind threshold of PFO combined with that thresholds dependence on the 
interaction of the other membrane constituent with cholesterol [19].  While 
cholesterol accessibility is necessary for PFO binding, the analysis of PFO 
derivatives with modifications on D4 revealed that sterol accessibility is not 
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sufficient to trigger stable PFO-membrane association [86]. As mentioned above, 
native PFO readily binds to model membranes containing 40 mol% cholesterol 
[and an equimolar mixture of other phospholipids, see 86], revealing that 
cholesterol is accessible at the membrane surface. However, the PFO
C459A
 
derivative was not able to bind to the same membranes, clearly indicating that the 
cholesterol molecules were not sufficiently accessible to trigger toxin binding. 
Binding of the PFO
C459A
 derivative was recovered when the cholesterol 
concentration was increased past 45 mol%, suggesting that the affinity of this 
derivative for cholesterol is lower than that of native PFO, and more cholesterol 
was required at the membrane surface to trigger stable binding.  In addition to 
this, Tweten et. al. recently mutated most of the amino acids in the loops of D4 to 
alanine and tested the mutation effect on the binding of PFO [98].  These 
mutations greatly affected the amount of protein that could bind to a model 
membrane both positively and negatively; this shows that the protein was not 
simply binding to accessible cholesterol.   It is not clear how cholesterol 
accessibility varies with increasing amount of cholesterol in the membranes. For 
simplicity, I have represented this variation as a linear function of cholesterol 
concentration, (Fig. 1.4) however, cholesterol accessibility may have a non-linear 
dependence in these systems. Further investigations are required in this area to 
establish the precise mechanism of PFO-cholesterol interaction as a function of 
cholesterol accessibility. 
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1.6 Mutations in Domain 4 Affect the Cholesterol Threshold Required to 
Trigger Binding 
 Our lab has recently shown that by modification of the C459 reside in the 
binding domain of PFO, we were able to decrease the “cholesterol threshold” of a 
PFO derivative [86]. While PFO has long been put forth as a probe for 
cholesterol-rich membranes, the advent of new PFO derivatives with varied 
“cholesterol thresholds” adds a layer of selectivity to the cholesterol sensing 
measurements. The development of PFO derivatives with varied binding 
thresholds would allow for the detection of various grades of cholesterol 
accessibility.   
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CHAPTER 2 
MODIFICATIONS IN PERFRINGOLYSIN O DOMAIN 
4 ALTER THE THRESHOLD OF CHOLESTEROL 
CONCENTRATION REQUIRED FOR BINDING 
The majority of this chapter is the result of collaboration and is taken from:  
 
Benjamin B. Johnson, Paul C. Moe, David Wang, Kathleen Rossi, Bernardo L. 
Trigatti, and Alejandro P. Heuck (2012)"Modifications in Perfringolysin O 
Domain 4 Alter the Cholesterol Concentration Threshold Required for Binding" 
Biochemistry 51.16 (2012): 3373-3382. 
2.1 Introduction 
 Among the most powerful tools to determine the localization and 
fluctuations of molecules, in the physiological context of intact living cells, are 
fluorescence microscopy and related techniques. Visualization of cholesterol 
molecules in membranes is only limited by the molecular probes available to 
directly determine cholesterol levels [99, 100]. Cholesterol-binding reagents such 
as filipin have been widely used to stain cholesterol in cell membranes 
[101],[102]. However, given the ubiquitous distribution of cholesterol in 
mammalian cells, membrane permeable filipin, as well as other cholesterol 
fluorescent analogs commonly employed as imaging probes, [2],[100] stain all 
membranes (i.e., plasma and inner membranes) independently of their cholesterol 
levels [103]. Clearly, better molecular probes could facilitate the detection of 
cholesterol levels in cell membranes and their fluctuation in response to metabolic 
signals and drug therapies. 
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Non-lytic derivatives of the cholesterol-dependent cytolysin (CDC) 
Perfringolysin O (PFO) have been used to detect cholesterol rich microdomains in 
cell membranes [104]. The sharp transition observed for PFO binding to model 
membranes containing increasing amounts of cholesterol suggests that the toxin 
could be used as a molecular probe to detect cholesterol levels on cell membranes. 
Unfortunately, the promise of PFO as cholesterol imaging probe is limited by the 
narrow spectra of cholesterol concentrations that can be discriminated by the 
native toxin.  
We have recently found that the C459A modification of the membrane 
interacting domain of PFO D4 alters the cholesterol concentration threshold 
required for binding [105]. I reasoned that additional modifications may yield 
PFO derivatives that bind to membranes containing more or less cholesterol than 
the native toxin. By combining the tunable properties of PFO D4 with the many 
fluorescent probes available [99], it would be possible to generate imaging 
reagents capable of detecting a broad range of distinct cholesterol levels in cell 
membranes. 
I have modified residues located in the proximity of Cys459 and these 
modifications resulted in an increase, or decrease, in the amount of cholesterol 
required to trigger PFO binding. We then demonstrated these varied cholesterol 
requirements on both model and cell membranes.       
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Figure 2.1 PFO D4 showing the location of residues modified in this study. A. 
Cartoon representation of the -carbon backbone for PFO (upper right) with D4 
showed in green, and for the -carbon backbone and amino acids surface side-
view of PFO D4. The conserved undecapeptide (red), the C459 (blue), the 3 loops 
(L1, L2, and L3) located at the tip of D4 (yellow) and the C-terminus are 
indicated. B. Bottom-view of the cartoon representation shown in A, with amino 
acids mentioned in the text shown as sticks and labeled. The central region 
containing mutations that affect the cholesterol threshold of the toxin is 
surrounded by an oval. The PFO D4 image was rendered in PyMol (DeLano 
Scientific). 
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Table 1: PFO Background Mutations Abbreviation 
 
 
 
 
 
2.2 Results 
2.2.1 The amount of cholesterol required to trigger PFO binding to a 
membrane is affected by amino acids located around the conserved Cys459. 
 
The binding of PFO to model membranes is regulated by both the lipid 
composition of the membrane and the structure of the loops located at the distal 
tip of D4 (Fig. 2.1A). The presence of “free” cholesterol molecules at the 
membrane surface is required to trigger PFO-membrane association [19, 20, 39, 
62]. However, how many of these “free” cholesterol molecules are required to 
trigger binding seems to be dictated by the structure of the D4 loops. Using 
POPC-cholesterol liposomes as model membranes, we have shown that the 
Cys459 to Ala substitution increased the threshold for cholesterol binding from 30 
mol% to 35 mol% [20]. This was surprising because it has been shown that only 
the loop1 (L1), loop 2 (L2), and loop 3 (L3) in D4 mediate the specific interaction 
of PFO with cholesterol [83], with only two residues (Thr 490 and Leu491) being 
essential for cholesterol recognition [85]. It is clear from these data that the 
precise role of cholesterol in the cooperative cytolytic mechanism of PFO is far 
from being understood. 
Table1:  PFO Background Mutations Abbreviation 
 Mutations 
nPFO None, Wild Type 
rPFO C459A 
FPFO C459A-E167C-F318A 
pPFO C459A-E167C-F318A-Y181A 
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I first investigated if the phospholipid composition of the membrane 
affected the differential binding of native nPFO and the Cys-less rPFO, and 
second, if modifications to residues that are known to interact with the  
membrane upon PFO binding further affected the cholesterol binding threshold of 
the toxin [60]. The cholesterol content of the liposomes was varied from 25 mol% 
to 50 mol% and the phospholipid composition was fixed at a 1:1:1 molar ratio of 
POPC, POPE, and SM (the most abundant human plasma membrane 
phospholipids). In membranes containing just POPC:cholesterol, the cholesterol 
threshold for nPFO and rPFO binding are 40 mol% and 44 mol% cholesterol [20]. 
In membranes containing POPC, POPE, and SM, the cholesterol thresholds for 
nPFO and rPFO binding was 36.5 mol% and 41.5 mol% cholesterol, respectively. 
Interestingly, despite this both PFO derivatives showed a lower cholesterol 
threshold when using a more complex phospholipid mixture, the cholesterol 
mol% difference between the PFO derivatives remained constant (Fig. 2.2A). 
Four mutants in the Cys-less rPFO derivative, L491C (in L1), A401C and 
V403C (in L2), and A437C (in L3) [Fig. 1, 60] were initially tested to evaluate 
the effect of D4 mutations on the cholesterol dependent binding of PFO. The pore 
forming activity of these derivatives is similar to that of nPFO when measured 
using liposomes containing high cholesterol [60]. Two of the analyzed mutants, 
rPFO
L491C
 and rPFO
V403C
 showed a 4-5 mol% increase in the cholesterol 
concentration required to trigger binding (Fig. 2.2A). No major change was 
observed for the A437C mutant and a minimal change for the A401C substitution. 
A close inspection of the structure of the D4 distal tip shows that the Leu491 and  
 46 
 
 
 
 
 
 
 
 47 
 
 
 
 
Figure 2.2 Mutations on D4 alter the cholesterol threshold of PFO. A. The 
fraction of bound PFO derivatives (0.1 µM final concentration) to liposomes of 
varying cholesterol content and POPC, POPE and SM in a constant 1:1:1 ratio 
(0.1 mM total lipid final concentration) was determined using intrinsic Trp 
fluorescence as described in experimental procedures. The cholesterol threshold 
for both nPFO and rPFO were lower than the ones observed with 
POPC:cholesterol (28), but the difference in the cholesterol threshold (~5 mol% 
cholesterol) was not significantly affected by the change on the phospholipid 
composition of the membrane. More than 4 mol% increase in the cholesterol 
threshold was observed for the rPFO
V403C
 and rPFO
L491C
 mutants.  B. Urea 
denaturation for rPFO
L491C
, the derivative with the highest cholesterol threshold. 
The average energy of emission for each fluorescence emission spectrum was 
obtained at given urea concentrations. The data were fitted assuming that the 
average energy of emission of the folded and unfolded states varies linearly with 
urea concentration.  C. Binding of nPFO (filled circles) and rPFO
L491C
 (open 
diamonds) to cholesterol dispersed in aqueous buffer solution. Trp emission 
intensity for 0.1 µM protein was measured as described in experimental 
procedures before (F0) or after (F) addition of the indicated amount of 
cholesterol. Most data points show the average of at least two independent 
measurements and their range. 
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Val403 residues are proximal to Cys459 (Fig. 2.1B), while the A401 and A437 
are more distant from the undecapeptide. To evaluate the potential effect of D4 
mutations on the conformational stability of the protein we determined the free 
energy for the unfolding of rPFO
L491C
, the protein with the highest cholesterol 
threshold, using equilibrium urea denaturation [Fig. 2B, 20]. No significant 
difference on the GU-F
water
 was observed between the rPFO and rPFO
L491C
 
mutant [13.6  1.5 kcal mol-1 [20] and 13.2  1.6 kcal mol-1, respectively]. These 
results suggest that mutations that altered the cholesterol threshold of rPFO did 
not affect the stability of the toxin. Moreover, nPFO, and rPFO
L491C 
bound 
similarly to cholesterol dispersed in aqueous buffer (Fig. 2C) [62], suggesting that 
the change in the cholesterol threshold is not related to the ability of the proteins 
to bind cholesterol. The lower maximum F/F0 observed for rPFO
L491C
 is typical 
for PFO derivatives containing the Cys459 to Ala mutation, which have higher F0 
[20]. 
2.2.2 A standard scale to evaluate binding properties of PFO mutants.  
The changes in the intrinsic Trp fluorescence that follows membrane 
binding of PFO derivative have been effectively used to determine the fraction of 
protein bound as a function of cholesterol concentration [19-21, 26, 62]. The step-
like increase on Trp emission intensity for PFO derivatives occurred at a precise 
cholesterol concentration (Fig. 2.2A). Each PFO derivative is therefore 
characterized by a cholesterol threshold defined as the cholesterol concentration at 
which the increase in Trp emission is half of the emission when binding is 
complete. Since the absolute cholesterol threshold (mol%) depends on the lipid 
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composition of the membranes (see above) and there are small variations in the 
cholesterol concentration among identically prepared liposome batches (~5 mol% 
in our hands), it is convenient to define a relative value for the cholesterol 
threshold rather than an “absolute” value. The difference in the cholesterol 
threshold (mol% cholesterol obtained with the same membranes) between nPFO 
and the PFO mutant under study is a more robust parameter to characterize the 
cholesterol binding properties of PFO derivatives. A negative value of mol% 
cholesterol indicates a derivative that binds at lower cholesterol concentrations 
than nPFO, and a positive value indicates that higher cholesterol concentrations 
are required for binding. For example, we previously found that rPFO required 
more cholesterol than nPFO for membrane binding [20]. Using the above defined 
relative scale the corresponding mol% cholesterol for rPFO is +3.6. The 
absolute cholesterol threshold value for any PFO derivative can be calculated 
using the mol% cholesterol data if the value for nPFO is known for a particular 
membrane system.  Therefore, I determined the cholesterol threshold for nPFO by 
quantification of the lipid composition of liposomes containing 1:1:1 
POPC:POPE:SM and various amounts of cholesterol (Fig. 2.3A). The cholesterol 
threshold of nPFO was 36.5  1 mol% cholesterol for this membrane system. 
2.2.3 Mutations on D4 can increase or decrease the mol% cholesterol of 
PFO derivatives.  
Our ultimate goal is to obtain probes that differentially bind to cellular 
membranes containing different cholesterol levels. We therefore introduced single 
amino acid mutations into PFO D4 using the parental rPFO
E167C-F318A
 derivative  
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Figure 2.3 Cholesterol thresholds in PFO derivatives can differ up to 10 
mol% cholesterol. A. Determination of the cholesterol threshold for nPFO (200 
nM final concentration) on POPC:POPE:SM membranes containing the indicated 
mol % of cholesterol (100 µM total lipids final concentration). The mol % of 
cholesterol was determined by individual quantification of cholesterol and total 
phospholipids. Cholesterol was quantified using Amplex® Red and total 
phospholipids by phosphate determination after acid hydrolysis as described in 
section 2.4.7. Thin lines are a guide for the eye to indicate average range for data 
in the transition. B. Cholesterol dependent binding of FPFO
D434S
 (open triangles) 
and FPFO
L491S
 (open squares) derivatives selected for cellular studies compared to 
nPFO (filled circles), rPFO (open circles), and FPFO (filled star). Binding 
measurements were done as indicated in Fig. 2.2 Data points are the average of at 
least two measurements and their standard deviation. 
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(hereafter named FPFO). The F318A mutation renders a protein that oligomerize 
on liposomal membranes but is not lytic at 1/1000 protein/total-lipid ratio  
concentrations [59], and increases by more than 20-fold the magnitude of toxin 
required to cause 50% hemolysis in sheep red blood cells (Fig. 2.4). The E167C 
mutation introduces a unique site for labeling with a fluorescent or 
other probe of choice, and this modification does not affect the properties of the 
toxin[56, 62]. We first evaluated the cholesterol threshold for the parental FPFO 
derivative, which contains the same D4 as rPFO. The mol% cholesterol for 
FPFO was +3.2  0.5, very similar to that observed for rPFO (Fig. 2.3B). This 
result clearly indicated that neither the F318A mutation in D3, nor the E167C 
mutation in D1, affected the cholesterol binding properties of the toxin. Our next 
goal was to scan the D4 loops for mutations that reduced or increased the 
cholesterol threshold of FPFO. 
The first candidate to decrease the cholesterol threshold was the charged 
D434 residue located in L3 of PFO D4. The negatively charged Asp was modified 
to Ser, a non-charged amino acid that can form hydrogen bonds with the polar 
groups of the lipids at the membrane surface. The mol% cholesterol for the 
FPFO
D434S
 decreased ~3 units, rendering a derivative with a lower cholesterol 
threshold than the parental FPFO derivative and very similar to the one for nPFO 
(Fig. 2.3B). 
With the goal of increasing the cholesterol threshold of FPFO derivative to 
higher cholesterol concentrations we targeted the L491 residue because it has 
been shown that the L491A mutation decreased PFO binding as determined using  
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Figure 2.4 Percentage of hemolysis of sheep red blood cells for PFO 
derivatives as a function of protein concentration. Washed sheep red blood 
cells (RBC) were exposed to the indicated concentration of FPFO(●), rPFO(●),  
and nPFO(●), with addition of BSA to maintain overall protein levels. This 
mixture was then incubated for 30 minutes at 37°C. Unlysed RBC were removed 
by centrifugation. The extent of hemoglobin release was quantified by measuring 
the absorbance of the supernatants. 
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surface plasmon resonance [85]. We replaced the hydrophobic Leu for the more 
polar residue Ser generating the FPFOL491S derivative. As expected, 
FPFOL491S showed a cholesterol threshold seven units higher than the parental 
FPFO (Fig.2.3B). Both FPFO
D434S
 and FPFO
L491S
 were selected for cellular studies 
because the cholesterol threshold between them differ more than 10 mol % 
cholesterol. 
2.2.4 Cholesterol was essential for PFO binding to murine macrophages-like 
cells.  
We tested if the binding of the parental FPFO
Alexa488
 derivative was dependent on 
cholesterol at the surface of the plasma membrane of murine macrophage-like 
cells (RAW 264.7) using two independent assays. First, we incubated RAW 264.7 
cells with filipin to block cholesterol at the membrane surface [36, 106, 107]. 
While filipin fluorescence was seen both at the cell surface, as well as 
intracellularly, (Fig. 2.5A), FPFO
Alexa488
 was found only at the surface of untreated 
murine macrophage-like cells. In contrast, when cells were first treated with 
filipin no significant binding of FPFO
Alexa488
 was detected on the cell surface (Fig. 
2.5A). Cholera toxin subunit B associates with lipid rafts in plasma membranes by 
binding to the ganglioside, GM1 in a cholesterol independent manner [108]. 
Labeling of cells with CTxB
Alexa594
 was not affected by filipin treatment, 
demonstrating that filipin treatment did not disrupt the plasma membrane but 
specifically blocked FPFO
Alexa488 
binding. Second, we tested the cholesterol 
dependence of FPFO
Alexa488
 binding to RAW 264.7 cells by removing cholesterol 
from the membrane surface using incubation with mCD [109]. Cells were 
incubated with 0.05 mM, 0.5 mM, or 5 mM mCD for 3 h at 37 oC. Treatment of 
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cells with 0.5 mM or higher mCD concentrations prevented labeling with 
FPFO
Alexa488
, whereas treatment with 0.05 mM (Fig 2.5B) or lower concentrations 
had no apparent effect (data not shown). In contrast, mCD treatment of cells did 
not affect the extent of CTxB
Alexa594
 binding. It is clear from these data that 
binding of FPFO
Alexa488
 to RAW 264.7 cells membranes was dependent on the 
presence of cholesterol and regulated by the cholesterol levels at the membrane 
surface. 
2.2.5 The sensitivity of PFO mutants for cholesterol concentration was 
conserved on RAW 264.7 cells membranes.  
The cholesterol content of the cell membranes can be altered by incubations with 
mCD or mixtures of mCD:cholesterol [109]. Incubations with mCD alone or 
with high mCD:cholesterol ratios reduce the cholesterol concentration on the 
plasma membrane. In contrast, incubation with low mCD:cholesterol ratios 
increase the cholesterol content of the cells [106, 110]. We therefore incubated 
RAW 264.7 cells with 2.5 mM mCD alone or with mixtures of 2.5 mM 
mCD:cholesterol at ratios ranging from 20:1 to 3:1 in order to decrease and 
increase the normal levels of cholesterol in the plasma membrane (Fig. 2.6). 
Binding of FPFO
Alexa488
 was not observed in cells treated with mCD alone (as in 
Fig 2.5B), or with a mCD:cholesterol ratio of 20:1 (Fig. 2.6). Cells treated with a 
mCD:cholesterol ratio of 15:1 were labeled faintly (slightly less than untreated 
cells) by FPFO
Alexa488
.  In contrast, treatment of cells with mCD:cholesterol 
ratios of 8:1 or lower resulted in substantially more labeling with FPFO
Alexa488
. 
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Figure 2.5 Cholesterol modulates FPFO binding to RAW 264.7. A. Filipin 
blocks FPFO
Alexa488
 binding to the cell surface. Fixed RAW 264.7 murine 
macrophage-like cells were incubated without (top row) or with 7.6 µM filipin 
(bottom row) for 60 min at 20-23 
o
C. Cells were washed and incubated with 
FPFO
Alexa488
 (40 nM) and CTxB
Alexa594
 (5 µg/mL) (the latter as a marker for the 
cell surface). B. Depletion of cholesterol using mCD inhibits FPFO
Alexa488
 
binding. Cells were treated for 2 h without (panels marked “0”) or with the 
indicated amount of mCD. Cells were then fixed and incubated with FPFO
Alexa 
488
 and CTxB
Alexa594
 for 90 min, and then stained with DAPI for nuclear DNA as 
described in experimental procedures. Labeled cells were imaged by wide field 
fluorescence microscopy using standard filter sets for TRITC (“Red” CTxB 
labeling), FITC (“Green”, FPFO
488Alexa), or DAPI (“Blue”, filipin labeling in A, 
DAPI labeling in B). Scale bars represent 10 µm. 
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The FPFOD434S-Alexa633 derivative was bound to the plasma 
e, suggesting that the 
cholesterol dependent properties of PFO derivatives observed with model 
membranes are conserved on natural membranes (i.e., RAW 264.7 cells). A slight 
increase in ratio of 20:1, and more than two fold increase when cells were treated 
with ratios of 15:1 or lower. Interestingly, untreated cells did not significantly 
bind the FPFO
L491S-Alexa488 
derivative, suggesting that the cholesterol availability in 
these cells is lower than the one obtained in model membranes with 50 mol% 
cholesterol. Binding of this derivative was observed only on cells overloaded with 
cholesterol using the lowest mCD:cholesterol ratios (Fig. 2.6). Taken together, 
our data clearly indicate that engineered PFO derivatives (e.g., FPFO) could be 
tuned to associate with cellular membranes containing different cholesterol levels. 
2.3 Discussion  
My studies on the role of the membrane interacting domain of PFO 
showed that mutations in amino acids located in the proximity of the conserved 
Cys459 modulated the threshold of cholesterol required to trigger toxin-
membrane association. Cholesterol was required at the plasma membrane for PFO 
binding to RAW 264.7 cells as determined by both filipin inhibition, and 
cholesterol depletion using mCD. The cholesterol-dependent properties of PFO 
derivatives were consistent on model as well as natural membranes, and not 
significantly affected by the lipid composition. Mutations of conserved residues 
increased or decreased the cholesterol threshold for PFO binding, suggesting that 
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Figure 2.6 Different cholesterol levels are distinguished by PFO derivatives on murine macrophage-like cells 
membranes. RAW 264.7 cells were incubated for 3 h at 37 ºC either with no additions (panels marked “None”), 2.5 mM 
mCD alone, or with 2.5 mM mCD complexed with cholesterol at the indicated mCD:cholesterol ratios. After 3 h, cells 
were washed, fixed, and incubated with 38 nM of either FPFO
Alexa 488 
 (top row), FPFO
D434S Alexa 633
 (middle row) or FPFO
L491S 
Alexa 633
 (bottom row). Cells labeled with FPFO
D434S Alexa 633
 or FPFO
L491S Alexa 633
 were also incubated with DAPI (middle and 
bottom rows). Cells treated with mCD:cholesterol ratios of 6:1 and 3:1 were not incubated with FPFO
D434S Alexa 633
 (middle 
row). Scale bars represent 10 µm. 
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PFO has evolved to recognize optimal cholesterol accessibility on cell 
membranes. High levels of cholesterol are required in model membranes to 
trigger binding of PFO and other related CDCs [26, 78-80]. Similar high-
cholesterol dependent effects have been observed for the enzymatic activity of 
cholesterol modifying enzymes [e.g., cholesterol oxidase, 111, 112] and for the 
rate of removal of sterols from the membrane surface by cyclodextrins [16, 113]. 
The high cholesterol levels needed for these membrane processes has been related 
to the tight interaction of cholesterol molecules with surrounded phospholipids 
[114, 115]. Cholesterol becomes accessible at the membrane surface only after the 
sterol-phospholipid interaction is saturated [116, 117]. The interactions of 
cholesterol with phospholipids make the phospholipid-sterol mixtures in 
membranes non-ideal, and therefore the thermodynamic parameter that more 
precisely relates to the cholesterol concentration with the accessibility of sterol 
molecules at the membrane surface is the chemical activity. Cholesterol 
accessibility is influenced by changes in the length and saturation of the acyl 
chains of the phospholipids present in the membrane, as well as by the size of the 
phospholipid head groups [22]. Given that the levels of cholesterol on the plasma 
membrane seem to be tightly regulated [32, 118], it is not unexpected that PFO 
has evolved to maximize the recognition of a particular cholesterol accessibility 
[39]. 
PFO contacts the target membrane via D4 [26], the loops at the bottom of 
the beta sandwich being the only segments of this domain that remain membrane 
inserted after oligomerization [Fig. 1, 60]. Comparison of the sequences for 28 
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CDC family members shows that the conserved undecapeptide (458-468, PFO 
sequence), L1 (488-493) and L2 (398-406) contain five, four, and four invariable 
residues, respectively [39]. The less conserved L3 (434-439) has no invariable 
residues. Multiple mutagenesis studies have shown that residues located in the 
undecapeptide , especially the conserved Trp residues, are very important for 
pore-formation [reviewed in 119], and this undecapeptide was initially considered 
the cholesterol binding site of the CDCs. However, it has been shown that the L1-
L3 loops are responsible for the interaction of PFO with cholesterol containing 
membranes [83]. More recently, it has been suggested that only two invariable 
residues located in L1 are essential for cholesterol recognition: Thr 490 and Leu 
491 [85]. While it is clear that the side chain of T490 and L491 are critical for 
cholesterol binding, direct cholesterol interaction with these two residues has not 
been shown. It may be possible that these two mutations affected a membrane-
dependent conformational transition required for cholesterol interaction, and not 
the interaction with cholesterol itself. Moreover, the analysis of other invariable 
residues located in L1 (Gly488 and Pro493), and in L2 (H398, G400, and A404) 
has not been done, and therefore the exact location of a cholesterol binding site (if 
any) deserves further characterization. We have shown here either the mutation of 
L491 (a putative cholesterol binding residue) or V403 (not previously related to 
cholesterol interaction) significantly altered the cholesterol threshold for PFO 
binding. Surprisingly, none of these residues affected PFO binding or pore-
formation at high cholesterol concentration (Fig. 2.2). A similar effect was 
previously found for the C459A mutation in the undecapeptide [Fig. 2A, 20]. 
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Moreover, elimination of the negative charge of Asp434 located in the poorly 
conserved L3 segment decreased the cholesterol threshold for PFO (Fig. 2.3B). It 
is therefore clear that the nature of amino acids located in D4 loops modulates the 
cholesterol accessibility required to trigger toxin binding, with residues located 
around the conserved Cys459 being the ones that affected the cholesterol 
threshold the most (Fig. 2.1B). In addition to single amino acid substitutions, 
changes that are likely to affect the conformation of the protein, like the pH of the 
medium, also alter the cholesterol threshold for toxin binding [18, 89]. Taken 
together, these data strongly suggest that the conformation of the PFO D4 dictates 
the cholesterol accessibility required to trigger toxin binding. The importance of 
sensing an optimal cholesterol chemical activity is reflected in the highly 
conserved amino acid sequences at the membrane interacting loops of the CDCs. 
 Another important characteristic of PFO binding to cholesterol containing 
membranes is the typical step-wise increase that in our experiments was detected 
by the intrinsic Trp fluorescence change that follows the exposure of the aromatic 
residues to the membrane surface [18, 21, 26, 95]. This membrane-dependent 
fluorescence change constitutes an efficient approach to determine PFO binding 
(Fig. 2.3A). The association of PFO with membranes can also be detected by the 
formation of SDS-resistant oligomers using SDS-PAGE [18, 21, 48, 65]. Both 
approaches have independently shown PFO transition from no binding to 
complete binding in a very narrow window of cholesterol concentrations. In 
agreement with these results, we have shown, using simultaneous determinations 
of PFO binding and pore-formation, that the cholesterol-dependent response is 
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regulated during the initial binding step of the toxin [20]. The molecular basis for 
this sharp cooperative cholesterol-dependent PFO binding remains unknown. It 
has been suggested that either a sharp change in the cholesterol chemical activity 
or oligomerization preceded by a reversible PFO-cholesterol equilibrium may be 
responsible for the sharp change in the binding profile [21]. Similar binding 
profiles have been observed on membranes containing different levels of 
cholesterol (e.g., plasma membrane or ER membranes), indicating that similar 
cholesterol accessibilities can be obtained on membranes with very different 
cholesterol concentrations [21]. Independent of the mechanism, the effect on the 
cholesterol threshold for PFO binding observed when the phospholipid 
composition is modified, indicates that the cholesterol accessibility plays a critical 
role on the initial PFO-membrane interaction [18-20]. This cholesterol-dependent 
transition has been used to image membranes containing high cholesterol [120-
122]. Originally, it was suggested that PFO binds exclusively to cholesterol rich 
domains or membrane rafts [123, 124]. However it has become clear that PFO 
binding and membrane localization is not limited to the presence of a particular 
membrane domain [18-20, 62, 81]. Therefore, we reasoned that by combining the 
sharp on/off membrane association properties of PFO with the ability to alter the 
cholesterol binding threshold of the toxin would provide unique tools to study and 
clarify the cholesterol dependent binding mechanism of PFO to cellular 
membranes. 
Using site-directed mutagenesis we modified D4 of FPFO and obtained 
two derivatives, FPFO
D434S
 and FPFO
L491S
, each showing a distinctive cholesterol 
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dependent profile on model membranes. Binding of FPFO
D434S 
required ~3 mol% 
less cholesterol than FPFO, while binding of FPFO
L491S
 required ~7 mol% more 
cholesterol than the parental FPFO derivative (Fig. 2.3B). Based on the cholesterol 
dependent response obtained for FPFO on RAW 264.7 cells (Fig. 2.4), we 
determined if the differential binding properties of the proteins were conserved 
when using cellular membranes. In contrast to model membranes, the distribution 
and availability of cholesterol on cellular membranes could be affected by many 
factors, including membrane traffic, synthesis and modifications of lipids, 
presence of membrane proteins, and/or the association of the membrane with the 
cytoskeleton [125, 126]. The availability of cholesterol  on the plasma membrane 
of these cells was varied using incubations with mCD alone or different 
mCD:cholesterol mixtures [110]. The amount of mCD was maintained constant 
at 2.5 mM in all assays to account for any non-specific effect that this compound 
may have on membranes (e.g., removal of other lipids). Interestingly, similar 
cholesterol dependent properties were observed for PFO derivatives on biological 
membranes. Only FPFO and FPFO
D434S
 interacted with RAW 264.7 cells (Fig. 
2.6). No significant binding of FPFO
L491S
 was detected on RAW 264.7 cells unless 
the cells were treated with the lowest mCD:cholesterol ratios (i.e., the highest 
cholesterol levels achieved with this procedure). In contrast, FPFO
D434S
 was bound 
to cells treated with mCD alone (i.e., the lowest cholesterol level achieved). 
Based on the brighter spots observed along some faint outlines of the plasma 
membrane, we can speculate that there is heterogeneity in the distribution of 
cholesterol in the plasma membrane. As observed with model membranes, the 
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binding properties of the parental FPFO derivative on the membranes  of RAW 
264.7 cells were intermediate when compared with the properties observed for 
FPFO
D434S
 and FPFO
L491S
 (Fig. 2.6). 
In summary, we have shown here that modifications on PFO D4 altered 
the cholesterol binding properties of the toxin. Moreover, engineered PFO 
derivatives differentially bind to model and biological membranes containing 
different cholesterol levels. The plasticity of the PFO-cholesterol interaction 
combined with engineered PFO derivatives will allow us and others to create 
novel molecular probes to study cholesterol distribution and dynamics on cellular 
membranes. 
 
2.4 Methods 
2.4.1 Preparation of PFO Derivatives  
The expression and purification of the PFO derivatives were done as 
described previously [19, 127, 128]. The PFO derivative containing the native 
sequence (amino acids 29−500) plus the polyhistidine tag that came from the 
pRSETB vector (Invitrogen) is named nPFO [19]. The PFO Cys-less derivative 
(nPFO
C459A
, where Cys459 is replaced by Ala) is named rPFO [128]. The single-
Cys lysis-impaired parental derivative used in this study (rPFO
E167C
 
-F318A
) was 
named FPFO. The E167C mutation on domain 1 (D1) provides a site for specific 
probe attachment [56], and the F318A mutations on D3 eliminate the lytic activity 
of the toxin on liposomes [66]. Mutagenesis of PFO was done using the 
QuickChange (Stratagene) procedure as described previously [129]. 
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2.4.2 Steady-State Fluorescence Spectroscopy  
Steady-state fluorescence measurements were taken using a Fluorolog-3 
photon-counting spectrofluorometer as described previously [105]. Samples were 
equilibrated at 25 
o
C before fluorescence determinations. 
2.4.3 Assay for Binding  
Binding to liposomes was done using the change in the Trp emission 
intensity produced by the binding of PFO to cholesterol containing membranes as 
described previously [105]. Briefly, emission for Trp fluorescence was recorded 
at 348 nm (4 nm bandpass) with the excitation wavelength fixed at 295 nm (2 nm 
bandpass). The signal of monomeric PFO derivatives were obtained with samples 
containing 200 nM protein in buffer A (HEPES 50mM, NaCl 100mM, DTT 
1mM, EDTA 0.5mM, pH 7.5) using 4 mm x 4 mm quartz cuvettes [130]. The net 
emission intensity (F0) for monomers was obtained after subtracting the signal of 
the sample before the protein was added. Liposomes were added (~200 M total 
lipids) and the samples were incubated 20 min at 37
o
C. Trp emission after 
membrane incubation was measured after re-equilibration of the sample at 25 
o
C, 
and the signal from an equivalent sample lacking the protein was subtracted (F). 
Fraction of protein bound was determined as (F-F0)/(Ff-F0), where Ff is the 
emission intensity when all the protein is bound. Binding of PFO derivatives to 
cholesterol dispersions in aqueous solutions was done as described previously 
[127]. 
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2.4.4 Urea unfolding equilibrium studies  
Unfolding was done as described previously [105]. The conformational 
stability of the proteins (ΔGU-F
water
), was calculated assuming a two-state 
unfolding model for the PFO monomers. 
2.4.5 Fluorescent protein labeling 
Fluorescent labeling was done as previously described [66],[131]. 
Maleimide derivatives of Alexa 488 or 633 were mixed with the PFO derivative 
of interest and incubated at room temperature for 2 h in buffer B (50 mM HEPES, 
100 mM NaCl, pH 8). Labeled PFO was separated from free dye by using size 
exclusion chromatography using Sephadex G-25 [1.5 cm (I.D.) x 25 cm column]. 
2.4.6 Preparation of Lipids and Liposomes 
Non-sterol lipids were obtained from Avanti Polar Lipids (Alabaster, AL), 
and cholesterol was from Steraloids (Newport, RI). Large unilamellar vesicles 
were generated as described previously [132]. Briefly, equimolar mixtures of 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-oleoyl-
sn-glycero-3-phosphoethanolamine (POPE), and sphingomyelin (SM, porcine 
brain), were combined with the indicated amount of cholesterol (5-cholesten-3β-
ol) in chloroform. The thin film of lipids formed after chloroform evaporation was 
resuspended in buffer A and passed through an extruder equipped with 0.1 m 
filter 21 times. Liposomes were stored on ice and discarded after three weeks. 
2.4.7 Lipid determination  
The percentage of cholesterol in liposomes used in Fig. 2.3A was 
determined using the Amplex® Red Cholesterol Assay Kit (Invitrogen). Total 
phosphate quantification assay as described in Chen et al. [133]. Briefly, the lipid 
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samples (30 µL) were added to a mixture of 0.45 mL of 8.9 M sulfuric acid and 
0.15 mL of hydrogen peroxide (30 % v/v) and heated at 200-215 °C for 30 min. 
The sample is then allowed to cool down for 5 min at 20-23 °C and 3.9 mL of 
water, 0.5 mL of ammonium molybdate 20 mM, and 0.5 mL of ascorbic acid 0.57 
M were added and mixed after each addition. Samples were then heated at 100 °C 
for 5 min and the absorbance at 800 nm was determined after equilibration at 25 
°C. Readings were then compared to a standard curve obtained in parallel with 
samples of potassium phosphate of known concentrations to determine the 
concentration of individual samples. The mol% cholesterol in each sample was 
calculated as total cholesterol/(total phosphate + total cholesterol). For other 
experiments the concentration of lipids was calculated using the concentration of 
stock solutions (usually between ± 3% of measured concentrations). 
2.4.8 Preparation of cyclodextrin complexed with cholesterol 
Methyl-β-cyclodextrin (mβCD) and cholesterol were from Sigma-Aldrich 
Canada Ltd (Oakville, ON, Canada). mβCD: cholesterol complexes were prepared 
as described by Christian et al. [134]. Briefly, cholesterol dissolved in 
chloroform:methanol (1:1 by volume) was transferred to a glass tube and the 
solvent was evaporated under N2 gas passed through a 0.2 µm syringe filter. 
mβCD (2.5 mM in Dulbecco’s modified Eagle’s medium) was added to the 
cholesterol residue to the desired molar ratio of mβCD:cholesterol. Cholesterol 
was dissolved by sonication for 30 min in a bath sonicator, followed by mixing 
overnight at 37 ºC. Samples were sterilized by passage through 0.45 μm syringe 
filters and used immediately thereafter. All procedures were performed in glass. 
 67 
 
2.4.9 Cell culture  
All reagents for cell culture were from Life Technologies Inc (Burlington, 
ON Canada). RAW 264.7 murine macrophage-like cells were cultured in 
Dulbecco’s modified Eagle’s medium containing 10 % fetal bovine serum (heat 
inactivated), 2 mM L-glutamine, 50 units/mL penicillin and 50 µg/mL 
streptomycin. Cells were passaged when they reached 75% confluence by gentle 
scraping and plated at 1:5 in fresh media. Prior to each experiment, 3x105 cells 
were seeded into each well of 8-well Nunc LabTek Chambered Coverglass 
(Thermo Scientific) and cultured for 24 h. 
2.4.10 Treatment of cells, labeling, and fluorescence microscopy  
Cells were treated for 1-3 h at 37 °C with media containing either filipin 
(5 µg/mL; Sigma-Aldrich Canada Ltd, Oakville, ON, Canada), mβCD (at the 
concentrations indicated), 2.5 mM mβCD complexed to cholesterol at different 
mβCD:cholesterol ratios, or with no additions. Cells were then washed twice with 
PBS [KH2PO4 0.88 mM, Na2HPO4 6.4 mM, NaCl 136.8 mM, KCl 2.7 mM, pH 
7.4 (PBS) supplemented with 1mM CaCl2], fixed for 30 min at 23-25 °C with 
2.5% paraformaldehyde (freshly made in PBS), and washed twice with PBS.  
Cells were incubated with fluorescently labeled PFO derivatives (38 nM in PBS 
containing 1 mg/mL bovine serum albumin) as indicated, for 90 min at 37°C.  In 
some experiments, cholera toxin subunit B (CTxB) labeled with Alexa 594 (5 
µg/ml; Life Technologies Inc, Burlington ON Canada) was included in the 
incubation.  Cells were then washed once with PBS at 23-25 oC and for some 
experiments cells were stained with DAPI (4',6-diamidino-2-phenylindole, 300 
nM, 1 min in PBS at 20-23°C; Life Technologies Inc, Burlington ON Canada).  
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Cells were washed another three times with PBS at 23-25 °C and cPBS containing 
0.5 mM ascorbic acid (Sigma Chemical Co, St Louis, MO) was added. Cells were 
immediately imaged by wide-field fluorescence microscopy using either a Zeiss 
Axiovert 200 M or a Leica DMI 6000B fluorescent microscope. 
2.4.11 Hemolysis assay 
Washed sheep RBC were suspended in buffer 10 mM sodium phosphate, 
1.74 mM potassium phosphate, 137 mM NaCl, 2.7mM KCl, pH 7.4 to 0.5 %. 
PFO of varied concentration was then added to 685 μL of the RBC suspension in 
addition to BSA to maintain overall protein levels. This mixture was then 
incubated for 30 min at 37°C [129]. Unlysed RBC were removed from samples by 
centrifugation at 6000g for 5 min. The extent of hemoglobin release was 
quantified by measuring the absorbance of the supernatants at 540 nm. Controls 
were determined by osmotic shock of an identical amount of RBC with deionized 
water (100% lysis) or by incubation with no PFO (0% lysis). 
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CHAPTER 3 
DESIGN OF A PROBE TO MEASURE MEMBRANE 
CHOLESTEROL ACCESSIBILITY BASED ON THE 
CHOLESTEROL RECOGNITION AND BINDING 
PROPERTIES OF PERFRINGOLYSIN O 
3.1 Introduction 
  
Due to its highly hydrophobic nature, cholesterol locates below the surface 
of the membrane, with only the small, polar hydroxyl group oriented towards the 
water-membrane interface.  The interaction of cholesterol with other membrane 
lipids dictates the accessibility of cholesterol to interact with water-soluble 
molecules located outside of the membrane [27, 28, 32].  Interactions of the sterol 
with other molecules at the surface of the membrane will be dictated not only by 
total concentration, but also by the lipid composition of the membrane.  
Cholesterol accessibility is an important biologically property of cellular 
membranes. Changes in cholesterol accessibility have been suggested to affect 
cholesterol homeostasis, modulate cell signaling, protein binding, and sterol 
transport (reviewed in [32, 21]).    Current probes to study membrane cholesterol, 
such as filipin, can efficiently detect overall cholesterol concentration in 
membranes. Cholesterol accessibility does not directly correlate with sterol 
content, but is modulated by cholesterols interaction with the other membrane 
components.  As a result subtle changes in cholesterol content can have profound 
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effect on cholesterol accessibility and cell signaling [21]. Novel molecular probes 
to determine cholesterol accessibility, and not total cholesterol concentration, are 
required for these studies.  
Previous studies in our lab have shown that the binding of the bacterial 
toxin, Perfringolysin O (PFO), to cholesterol containing membranes has a strong 
response to small changes on the cholesterol content of the lipid bilayer. The 
transition from no binding to full binding occurs at a particular cholesterol level. 
The concentration of cholesterol at which the binding transition from off-on is 
referred to as the cholesterol threshold to trigger membrane binding. This 
threshold can be modulated by changes in the lipid composition of the membrane 
[19].  
Our lab has also shown that the cholesterol threshold for PFO binding can 
be modulated by amino acids substitutions at the C-terminus of the toxin (Fig. 
2.2A). We were able to both lower and raise the concentration of cholesterol that 
is required for binding (Fig. 2.3B), thus allowing for the detection of varied 
cholesterol accessibilities. These results greatly increased the usefulness of PFO 
as a probe for cholesterol accessibility, however, the FPFO probe used in my 
previous work proved ineffective for testing on live cells due to high levels of cell 
mortality.  In this chapter, I aimed to create a completely nonlytic probe for 
membrane cholesterol and used it to assay cholesterol associability on live cells.  
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Figure 3.1: Molecular structure of monomeric water-soluble Perfringolysin 
O    Crystal structure of PFO in a ribbon representation showing the mutations 
contained in the pPFO non-lytic parental derivative. The mutations E167C located 
in D1 (green) and C459A in D4 (blue) allows for specific labeling with a single 
fluorescent probe. The mutations in D3 (blue) Y181A and F318A produce a non-
lytic PFO derivative. (PDB ID: 1PFO) 
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3.2 Results 
3.2.1 Construction of a non-lytic PFO scaffold to be used in the development 
of probes to detect membrane cholesterol accessibility.  
In my initial probe design, I used the FPFO background which contained 
three modifications, two of which, C459A and E167C, were used to move the sole 
cysteine in the protein out of D4 to D1 where fluorescent labels would not affect 
binding (Fig. 3.1A). The third modification, F318A, had been reported to 
eliminate PFO pore forming activity when tested with model membranes [66].  
However, when tested with live RAW 264.7 cells the FPFO derivative caused 
considerable cell death and presumably maintained lytic activity (Fig. 3.2A).  As 
detection of cholesterol accessibility required no (or minimal) alterations to the 
analyzed membrane (i.e., no lipid removal due to pore formation), a non-lytic 
PFO scaffold must be constructed for the analysis of live cells. 
 Amino acid substitutions in D3 have been previously been shown to 
reduce the lytic activity of PFO, for example the Y181A modification, which was 
shown to eliminate pore formation activity of PFO on model membranes [66].  
The lytic activity of PFO derivatives containing modifications in D3 was tested 
using sheep erythrocytes, and quantified by hemoglobin release. The PFO 
derivative with Y181A modification, like those containing the F318A 
modification, proved to be considerably less lytic than the native PFO, but they 
were still lytic at high concentrations (Fig. 3.2B). 
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Figure 3.2: Two modifications in domain 3 are required to abolish PFO 
cytolysis.  A. Quantification of cell death for RAW 267.4 cells incubated with the 
indicated PFO derivatives for 20 min at 37°C (shaded bars) or 4°C (crosshatched 
bars). The graph shows the percentage of live cells after incubation with the 
indicated PFO derivative (final concentration 1µM) when compared to cells that 
were not exposed to the PFO derivative. Cell survival was determined counting 
death cells with trypan blue stain before and after incubation with PFO 
derivatives. B. Hemolytic activity of PFO derivatives shown by the quantity 
required to lyse sheep erythrocytes. The indicated amount of the pPFO(▲), 
FPFO(●), rPFO-Y181A(■), and nPFO(▼) was incubated with a 0.5 % solution of 
stacked erythrocytes for 20 min at 37°C in a 96 well plate (final volume 200µL). 
Percent hemolysis was determined by measuring hemoglobin release post-
incubation using absorbance at 540 nm in a plate reader. Total hemoglobin 
released was determined by osmotic lysis of erythrocytes with water.    
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When both modifications were introduced simultaneously, the resulting PFO 
derivative was 100,000 fold less lytic than the native PFO, and showed minimal 
cell death at 37°C for concentrations up to 10µM.  The Y181A modification was 
therefore added to our FPFO background. The resulting construct, named probe 
PFO (pPFO), was used as the background for all further testing.     
3.2.2 Modification of Y181A in D3 altered the cholesterol binding properties 
of the distal D4 
 While the introduction of the F318A modification into rPFO did not alter 
the cholesterol dependent properties of the toxin, I found that introduction of the 
Y181A modification into the FPFO derivative to obtain pPFO shifted the 
threshold for the cholesterol concentration required for toxin binding to levels 
very similar to the one observed for nPFO  (Fig 3.3). Allosteric coupling between 
D3 and D4 has been previously reported [135], however I showed here, that 
modifications in D3 not only effect the kinetics of protein binding, but also the 
mol% of cholesterol required to trigger binding (or threshold). It is worth noting 
that residues in D3 are more than 70Ǻ away from the tip of D4, which is directly 
involve in cholesterol recognition. This indicated that mutations in D3, far from 
the binding domain (D4), can significantly affect the cholesterol binding threshold 
of the protein.   
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Figure 3.3: Shift in binding created by Y181A modification A. Cholesterol 
dependent binding of pPFO (red) and nPFO (black). Binding measurements were 
done as indicated in Fig. 2.2 B. Cholesterol dependent binding of rPFO (red) and 
nPFO (black). Binding measurements were done as indicated in Fig. 2.2. Data 
points are the average of at least two measurements and their range or standard 
deviation is indicated.  
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Figure 3.4: pPFO derivatives with different cholesterol binding thresholds. 
A. Relative change on the cholesterol threshold for different pPFO derivatives 
compared to nPFO. The fraction of bound PFO derivatives (final concentration of 
0.2 μM) to liposomes of varying cholesterol content and POPC, POPE, and SM in 
a constant 1:1:1 molar ratio (final total lipid concentration of 0.2 mM) was 
determined using intrinsic Trp fluorescence as described in Experimental 
Procedures. The cholesterol threshold is the amount of cholesterol required in the 
membrane to bind 50% of a given PFO derivative. Each pPFO derivative binding 
threshold is represented by the mol %  between its binding and that of nPFO 
with the same membrane preparation. A positive value indicating the need for 
more cholesterol and a negative value indicating the need for less cholesterol. B. 
A cartoon depiction of the beta-sheets that make up D4.  The loops that interact 
with the membrane and the location of modified amino acids are indicated.  C. 
Cholesterol dependent binding of pPFO
D434S
(●), pPFO(■), and pPFOT490A(▲). 
These derivatives were selected for further live cell testing. Binding 
measurements were done as indicated in Fig. 2.2.  
 
 
C. 
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3.2.3 Modifications in PFO D3 also affect how modifications in D4 change the 
 threshold for the cholesterol concentration required to trigger binding 
As shown in Fig. 2.3B, introduction of the D434S and L491S into FPFO 
both increased and decreased the binding threshold for cholesterol, respectively. 
Unexpectedly, when the L491S modification was re-introduced into the non-lytic 
pPFO derivative, I observed a slight increase in the binding threshold for 
cholesterol (Fig. 3.4A).  This effect showed the complexity of the allosteric 
coupling between D3 and D4, that regulates the cholesterol dependent 
oligomerization of the toxin.  
 Structural analysis of the water-soluble PFO derivatives showed that the 
modification of Y181A induced a conformational change in D4, as revealed by 
the changes in the Trp fluorescence spectrum (Fig. 3.5A). Since 6 of the 7 Trp in 
PFO are located in D4, a change in the overall Trp fluorescence spectrum is a 
good indicator of conformational changes taking place in this domain. The pPFO 
spectrum shows a significant red shift compared to that of the rPFO of nPFO 
suggesting movement of one or more Trp to a more polar environment.      
 Changes in the overall secondary structure content were also observed 
when the CD spectrum of pPFO is compared with the one of nPFO.   The CD 
spectra of pPFO shows less intensity at 215 nm compared to the nPFO and rPFO 
spectra, this indicating less beta structure in the protein (Fig. 3.5B).  Therefore, 
the opposite effects observed when the same L491S modification was introduced 
in FPFO or pPFO can be explained by conformational changes induced by the 
Y181A modification in D3.   
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Figure 3.5: Characterization of pPFO background A. Far-UV CD spectra of 
nPFO and pPFO in 10 mM sodium phosphate buffer pH 7.5 at a total protein 
concentration of 2.0 μM.  B. Normalized fluorescence emission spectra of nPFO 
and pPFO recorded in HBS buffer (hepes 50 mM, NaCl 100 mM EDTA 1 mM, 
DTT 1 mM). The spectra were taken between 310-400 nm with an excitation 
wavelength of 295 nm, and the total protein concentration was 500 nM. 
A. 
B. 
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3.2.4 Modification of domain 4 loops results in changes to the cholesterol 
binding threshold of pPFO derivatives  
In addition to the D434S and L491S modifications mentioned above, other 
amino acids located in the D4 loops were modified in the new pPFO parental 
derivative to analyze the effect of  changes to the side chains (modifications for 
Ala) or the effect of introducing a hydrophobic amino acid (modifications for Val 
or Ile) (Fig. 3.4 A and B). Major effects were observed when the native side 
chains were replaced with Ala at positions D434 in loop 3, and for T490 and L491 
in loop 1. These last two amino acids were proposed to be the cholesterol binding 
motif in PFO [98].  However, modification of the hydrophobic L491 by Ser, or 
the hydrogen bond former Thr490 for Val, showed only minor effects on the 
cholesterol binding properties of pPFO, suggesting that the role of these two 
residues in loop 1 may differ from a specific sterol binding motif.  
Modifications at loop 2 (S399 to A or I, A401to G or V, and V403 to A) 
showed only minor effect on the cholesterol binding threshold. Interestingly, 
modification of A437 in loop 3 for the bulky and hydrophobic Val residue 
decreased the cholesterol binding threshold, suggesting that hydrophobic residues 
in these loops may increase the interaction of the toxin with membranes. 
However, modification of the negatively charged D434 by Val showed a smaller 
effect on the cholesterol binding threshold than that for the modification of D434 
for the polar Ser.  
Based on the results discussed above, two modifications were selected for 
the studies of cholesterol accessibility on live cells: D434S and L491A. These 
modifications showed significantly lower and higher cholesterol binding 
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thresholds, respectively when compared with the pPFO background (Fig. 3.4C).  
These two modifications, plus the pPFO background itself, constitute a set of 
derivatives that cover a broad range in cholesterol accessibilities. These three PFO 
derivatives were used to explore how cholesterol manipulations in cells with 
cyclodextrins alter cholesterol accessibility at the membrane surface.  
3.2.5 Manipulation of cell membrane cholesterol with cholesterol:methyl-β-
cyclodextrin complexes results in only moderate changes in cholesterol 
accessibility  
Having created completely non-lytic PFO derivatives that could recognize 
various cholesterol levels on model membranes, I moved into testing live cell 
membranes. As a proof of concept, I took RAW 264.7 cells and manipulated their 
plasma membranes with cyclodextrin/cholesterol complexes. Using these 
complexes in different ratios, I was able to both add and remove cholesterol from 
the plasma membrane. Any changes in cholesterol accessibility on the RAW cell 
membranes were detected using fluorescently labeled PFO derivatives and flow 
cytometry.   
 The binding isotherms for the PFO derivatives were obtained using live 
RAW 264.7 cells pre-treated with different cholesterol:MβCD ratios (Fig 3.6 . 
Interestingly, the range of cholesterol:MβCD ratios that did not induced 
considerable cell death, did not modified cholesterol accessibility enough to allow 
the binding of the pPFO
T490A
 derivative.  Attempts to add more cholesterol to the 
plasma membrane of the RAW 264.7 cell resulted in cell death. Moreover, the 
pPFO and pPFO
D434S
 binding to live RAW cells containing various cholesterol 
levels did not show the sigmoidal response observed with model membranes 
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(compare Fig. 3.4C and Fig. 3.6).Therefore, I conclude that cholesterol levels in 
RAW cell membranes are tightly regulated, and cannot reach levels as high as the 
ones obtained when using model membranes. This also indicates live cells ability 
to readily adjust the cholesterol levels in their cell membranes.  
3.2.6 Membranes with identical cholesterol content bind different amounts of 
pPFO derivatives  
When tested on RAW cells, the binding of pPFO
D434S
 was always higher 
than that observed for pPFO (Fig 3.6), independently of the overall cholesterol 
content of the cell membrane. This unexpected observation may result from the 
higher concentration of PFO derivatives used in the assay, which were required 
PFO detection in flow cytometry. These results suggested that at saturation 
binding levels, a particular membrane could accommodate more pPFO
D434S
 
molecules than pPFO molecules. In order to investigate this possibility, I tested 
the binding saturation of pPFO and pPFO
D434S
 on both model membranes and live 
cells.   
Using model membranes, 38% cholesterol was chosen as it is a 
concentration slightly over that required for 50% pPFO binding (Fig. 3.4C). At a 
1:1000 protein lipid ratio, only part of the added pPFO was bound, but pPFO
D434S
 
showed maximal binding.  The binding of the pPFO and pPFO
D434S
 derivatives 
were measured on these membranes using intrinsic Trp fluorescence as described 
previously. Samples containing increasing amount of protein were incubated with 
the same amount of total lipids. The binding of the pPFO derivative was lower 
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Figure 3.6: Differential binding of pPFO derivatives to RAW cells with 
altered cholesterol content. Quantification of binding of Alexa 488 labeled 
pPFO
D434S
 (Black), pPFO(Red), and pPFO
T490A
(Blue) to RAW cells pretreated 
with varied levels of cholesterol complexed with mβCD (5 mM, 1 hr incubation at 
37°C).  Cells were washed twice after incubations with mβCD/cholesterol and 
after incubation with pPFO derivatives (0.5 µM protein, for 20 min at 4 
o
C ) and 
binding was quantified using flow cytometry as described in experimental 
procedures. Horizontal lines indicate binding of each derivative to untreated cells. 
The pPFO
T490A
 derivative showed no binding to the cholesterol activity that could 
be achieved through treatment with mβCD:cholesterol complexes. Both the pPFO 
and pPFO
D434S
 showed differential binding in response to cholesterol treatment.  
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than the one observed for pPFO
D434S
 independently of how much protein was 
used in the assay (Fig. 3.7A).  A similar effect was observed when binding to live 
RAW 267.4 cells was measured as a function of protein concentration using flow 
cytometry (Fig. 3.7B). However, a stable saturation level was difficult to obtain 
with live cells because at high protein concentrations, endocytosis starts to 
contribute to the overall fluorescent signal due to the internalization of protein 
despite using low temperatures.  It is clear from these data that the D434S 
modification increased the number of protein molecules that can bind to a 
membrane at a particular cholesterol concentration. These observations suggested 
that PFO binds cholesterol and remains bound to it after oligomerization. 
3.2.7 PFO binding decreased the cholesterol accessibility of the membrane  
 The differential binding observed for pPFO and pPFO
D434S
 in model and 
natural membranes could be explained by two alternative hypothesis. The first 
hypothesis postulates that some pPFO derivatives require more cholesterol 
molecules than others, and therefore, for a certain cholesterol level, the derivative 
that required less cholesterol molecules will have a higher saturation point. The 
second hypothesis postulates that protein binding sequester cholesterol molecules 
up to the point that the accessibility drops below the binding threshold of the PFO 
derivative and not more binding is observed.  
In order to determine which of these hypotheses is correct, I used a 
sequential binding assay (Fig.3.8A). In this assay the membrane is first saturated 
with one PFO derivate, and the binding of a second PFO derivative is 
subsequently evaluated on the already saturated membrane.  If the PFO 
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Figure 3.7 Binding saturation Curves A. Binding saturation of pPFO (red) 
and pPFO
D434S
 (black) to liposomes containing 38% cholesterol content and 
POPC, POPE, and SM in a constant 1:1:1 molar ratio. Samples containing 
increasing concentrations of pPFO or pPFO
D434S
 were incubated with liposomes 
for 20 min at 37°C. Binding was determined as indicated in Fig. 2.2. B. Binding 
saturation of pPFO (red) and pPFO
D434S 
(black) to live RAW 264.7 cells.  
Concentration dependent binding of Alexa 488 labeled pPFO and pPFO
D434S
 (20 
min incubation at 4°C) to RAW cells determined using flow cytometry as 
described in Fig. 3.6. 
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derivatives bind different number of cholesterol molecules, no binding will be 
observed for the second derivative because all accessible cholesterol molecules 
will be bound to the first added derivative. In contrast, if binding of a PFO 
derivative decreases the overall cholesterol accessibility, at the saturation point 
for one derivative the cholesterol accessibility at the membrane surface will be 
just below the binding threshold for this derivative. Upon this point, only 
derivatives that require less cholesterol accessibility will bind to the membrane.  
The sequential binding assay was done using pPFO and pPFO
D434S
, two 
derivatives that showed a ~5 mol% difference in their cholesterol threshold 
required to trigger binding on model membranes (Fig. 3.4C). To maximize 
visualization of any difference in pPFO binding I used liposomes containing ~37 
mol% cholesterol, approximately the cholesterol threshold of pPFO.  Based on the 
isotherm showed in Fig. 3.4 C, only 30-40% of the added pPFO derivative will 
bind to these membranes, while saturation levels are expected for the pPFO
D434S
 
derivative.  
Binding was independently determined a) using the change in Trp 
emission intensity that follow membrane interaction as described in Section 3.4.9 
(Fig. 3.8B), and b) using a membrane floatation assay based on ultra-
centrifugation through different sucrose cushions (Fig. 3.8C).  In both cases, I 
observed that saturation of the membrane with pPFO did not eliminate the binding 
of the pPFO
D434S
 derivative. In contrast, when the addition of the derivatives was 
done in the reverse order, saturation with the pPFO
D434S
 blocked the binding of 
pPFO.  
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These data clearly support the hypothesis that postulate that the binding of 
a derivative reduced the cholesterol accessibility at the membrane surface. 
Binding of pPFO reduced accessibility to the point where no more binding of this 
derivative can occur. However, since the pPFO
D434S
 has a lower threshold for 
cholesterol, it could bind to membranes saturated with pPFO. Moreover, the total 
amount of toxin bound was similar independently of the order of addition. The 
amount of pPFO bound during the first step of the assay was equivalent to the 
reduction in biding observed for pPFO
D434S
 in the second step when compared to 
its biding to membranes not pre-incubated with pPFO.   
3.3 Discussion 
 These studies have demonstrated the non-lytic nature of the pPFO 
background as well as the determination of the effects many mutations to D4 have 
on the cholesterol binding threshold of the protein.  These determinations 
established a library of mutations for the purposes of cholesterol accessibility 
determination.  From this library, we selected three PFO derivatives for live cell 
testing.  pPFO and pPFO
D434S
 both showed binding that mirrored the modulation 
of the cells cholesterol concentration, but not the sigmoidal binding that was 
shown on model membranes.  Saturation binding curves demonstrated that 
different concentrations of PFO derivatives could bind to identical membranes.  
This led us to testing the sequential binding of two pPFO derivatives that showed 
that PFO derivative sequester cholesterol when they bind and there for lower the 
cholesterol accessibility of the membrane.  The culmination of these studies is not 
only a versatile probe for membrane cholesterol accessibility but also a better 
understanding of how PFO recognizes accessible cholesterol.      
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 My recent studies revealed the need for a less lytic PFO derivative to serve 
as the scaffold for the cholesterol accessibility probe.  Though both the Y181A 
and the F318A mutations were shown to completely eliminate the ability of PFO 
to form pores on model membranes and “exhibit less than 1% of the hemolytic 
activity of PFO
C459A
 on human erythrocytes” [136, 66] ,I still encountered 
significant cell death when using this background for live cell testing.  As the data 
shows, when the concentration of toxins used is increased, the lytic activity of the 
derivatives is regained.  This discrepancy is indicative of the manner in which 
PFO derivatives are generally tested.  The usage of percent hemolysis compared 
to the native toxin is problematic because it is highly influenced by the toxin/RBC 
or model membrane ratio. I have also shown that the effects of mutations are very 
dependent to how much cholesterol is available on the surface of the membrane.  
This has led me to define my mutants based on their cholesterol threshold relative 
to wild type or Δmol % cholesterol (section 2.2.2).  This system better represents 
the differences between mutants without the effects presented by concentration 
and other membrane constituents. 
 I showed in Fig. 3.2A that a significantly high level of toxin is required to 
lyse sheep RBC compared to the same mutant in Fig 2.4.  While I maintain the 
same concentration and ratio from previous testing, the discrepancy is due to the 
fact that previous samples contained 10% glycerol.  I have seen that glycerol 
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Figure 3.8: Sequential binding of pPFO derivatives showed that PFO 
binding reduced cholesterol accessibility. A. Carton representation of 
experimental method from Part B. In brief two binding reaction take place to the 
same set of liposomes in succession with total binding being determined for each 
reaction. Each reaction contain a PFO derivative with either a high (red ovals) or 
low (green ovals) cholesterol binding threshold.   B.First exsperiment Liposomes 
with cholesterol content just above the threshold for pPFO binding were saturated 
with pPFO (100 nM protein, 100 µM total lipids) and incubated for 20 min at 
37
o
C. After equilibration, bound protein was quantified using intrinsic Trp 
fluorescence as indicated in Fig. 2.2A Subsequently an equimolar amount of 
pPFO
D434S
 was added to the sample, incubated for additional 20 min at 37
o
C, and 
bound protein determined as indicated in section 3.4.9  Second experiment. 
Same experiment described in A was performed but liposomes were first 
incubated with pPFO
D434S
, and subsequently incubated with the derivative with a 
lower cholesterol threshold pPFO.  C. pPFO (red) and pPFO
D434S 
(green) were 
bound in two separate sequential binding assays to the same liposomes as in A.  
The proteins were added in two sequential incubation in the order indicate one the 
graphs with the protein in parentheses tracked via an Alexa 488 tag.  The percent 
of bound protein was determined after both incubations using separation with 
ultra-centrifugation and, tracking of the fluorescence of the Alexa dyes.  
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significantly destabilized the membranes of cells and increased the lytic activity 
of the toxin. These current data represent a more accurate representation of the 
lytic activity of the protein, with slight variations from the age and health of the 
RBC notwithstanding.         
The addition of the Y181A mutation to my probe, while resulting in the 
almost completely non-lytic pPFO derivative, did have some unforeseen results.  
Residue Y181 is located in D3, far away from the cholesterol binding interface of 
the protein, but has seemed to causes a distortion in D4 (Fig. 3.1).  The Y181 
residue is thought to be involved in oligomerization by way of a π-stacking 
interaction that aids in aligning the beta sheets of the protein for insertion see 
section 1.5.2.2 [47].    As a result, this mutation has affected both the cholesterol 
binding threshold of pPFO, as well as the combined effect of other mutations 
upon the construct.  The effect of the Y181A mutation would seem to indicate a 
previously proposed interplay between D3 and D4 [127]. It is also possible that 
oligomerization affects the cholesterol threshold of the mutant.  PFO binding is 
very cooperative in nature, as shown by its sharp sigmoidal shaped binding 
isotherm.  A significant part of the oligomerization process is the disruption of the 
interface between D2 and D3 which is thought to be caused by a shift in D4.  The 
Y181 residue is located near the interface of D2 and D3 and may weaken the 
interaction between the two domains, thus, making the shift in D4 more 
energetically favorable. 
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 In order to find pPFO derivatives with varied cholesterol thresholds 
similar to our previous work, I mutated key amino acids in D4.   As a whole, I 
observed that mutations on the well conserved loops L1 and L2 have neutral or 
negative effects, whereas mutations to L3 had neutral or positive affects in terms 
of cholesterol threshold.  The two mutations with the most positive effect on 
cholesterol threshold, D434S and A437V, are both located in L3.  The mutation 
with the largest negative effect was T490A, which has been put forth as half of a 
cholesterol binding motif that also contains L491. While the mutation of T490 
significantly affects the binding of the protein, it still binds to membranes 
containing high cholesterol. The same is true for the L491 residue. A binding 
motif contains only two amino acids is unlikely to be able to afford losing either 
amino acid.  While these two amino acids are clearly very important for binding, 
further study is needed to determine if additional amino acids are involved.    
 My live cell testing shows a gradual increase in the binding levels of my 
probe when cholesterol in the cell membranes was increased or decreased (Fig. 
3.6).  This is not what I observed on model membranes where sharp sigmoidal 
isotherms were shown.   I attribute these results to the fact that live cells were 
used. Cholesterol accessibility is involved in many important cellular functions 
including cholesterol homeostasis.  The addition of cholesterol to the plasma 
membrane would have resulted in the trafficking of cholesterol to the ER for 
esterification and storage. Over time this would have reduced the cholesterol 
accessibility of the plasma membrane back to equilibrium. 
 93 
 
 By showing that PFO sequesters cholesterol upon binding I can also infer 
that the interaction of PFO with cholesterol is not transient and that it persists 
after oligomerization. The sequestration of cholesterol by PFO also suggests that 
PFO is lowering the cholesterol accessibility of the membrane by its binding.  
This indicates that any PFO derivative will lower the accessibility of cholesterol 
on the cell membrane to that of its binding threshold if its binding is saturated.  
PFO derivatives could hypothetically be used to reduce the level of accessible 
cholesterol on a cell membrane for the purpose of initiating trafficking of 
cholesterol to that membrane. This could open up an entirely novel use of PFO as 
a scientific tool.    
 
3.2 Methods   
3.4.1 Cell culture   
RAW264.7 macrophages were cultured in RPMI 1640: 10% FCS with 50 
units/mL penicillin and 50 µg/mL streptomycin at 37°C with 5% CO2.   Cell were 
passaged at 70-80% confluence by removal of nonadherent cells and adherent 
removed by gently pipetting cell were replated with fresh media in a one to ten 
dilution. 
3.4.2 Hemolysis of sheep red blood cells  
pPFO derivatives were dialyzed twice in 4 liters of PBS (10 mM sodium 
phosphate, 1.74 mM potassium phosphate, 137 mM NaCl, 2.7 mM KCl, pH 7.4) 
for 4 hrs to exchange buffers and remove cryoprotectant glycerol.  Washed RBC 
were suspended in PBS to 1%.  pPFO was serially diluted in a 96 well plate and 
then combined with an equal volume of the RBC dilution to a final concentration 
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of 250 µL per well.  This mixture was then incubated for 30 min at 37°C.  Non-
lysed RBC were pelleted from the samples by centrifugation at 3500g for 10 min 
and 200 µL of supernatant was transferred to a new plate. The extent of 
hemoglobin release was quantified by measuring the absorbance at 540 nm of cell 
free supernatants. Controls were determined by osmotic shock of an identical 
amount of RBC with deionized water (100% lysis) or by incubation of RBC in the 
absence of PFO (0% lysis). 
3.4.3 Flow cytometry   
Aliquots of 1 million cultured RAW 264.7cells were washed in PBS: 
1%FCS (Fetal calf serum) and then incubated at 37 °C for 30 min in 0.5 ml of 
PBS: 1% FCS with 5 mM MβCD complexed with varied concentration of 
cholesterol. The cells were then wash and incubated at 4 °C for 20 min with 0.5 
μM of the indicated PFO derivative in 100 μL of PBS: 1% FCS.  The cells were 
analyzed in a LSRII flow cytometer (BD Biosciences) to determine mean 
fluorescent intensity. 
3.4.4 Lysis of RAW 264.7 cells 
Cultured RAW cell were counted using a hemocytometer, and re-
suspended in PBS: 1% FCS.  Aliquots of 1 million cells were washed in PBS: 
1%FCS and then incubate at 4 °C and 37°C for 20 min with 1 µM of the indicated 
PFO derivative in 100 μL of PBS: 1% FCS.  Cells were then washed and 
recounted and compared to a sample containing no protein. 
3.4.5 Preparation of lipids and liposomes  
Large unilamellar vesicles were generated as described previously in 
section 2.4.6. Briefly, equimolar mixtures of 1-palmitoyl-2-oleoyl-sn-glycero-3-
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phosphocholine (POPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine (POPE), and sphingomyelin (brain, porcine), were 
combined with the indicated amount of cholesterol (5-cholesten-3β-ol).  
3.4.6 Florescent protein labeling  
Florescent labeling with Malemide derivatives of Alexa 488 or 633 was 
done as previously described in Section 2.4.5 
3.4.7 Assay for PFO binding to liposomes  
Binding assay was done using the change in the Trp emission intensity 
produced by the binding of PFO to cholesterol containing membranes as 
described previously Section 2.4.3 
3.4.8 Preparation of PFO derivatives 
The expression and purification of the PFO derivatives were done as 
described previously in Section 2.4.1   Aditional the Y181A  mutation on D3 in 
conjunction with the F318A mutation eliminate the lytic activity of the toxin [66], 
[105].  
3.4.9 Sequential binding of PFO derivatives determined using intrinsic 
tryptophan fluorescence 
The consecutive binding of two different PFO derivatives with different 
cholesterol binding thresholds was tested on model membranes containing 36 mol 
% cholesterol.  The first PFO derivative was added to a cuvette and Trp 
fluorescence was determined as described in (2.4.3).  Liposomes were then added 
and the sample was incubated for 20 min at 37 ºC. Bound PFO was determined by 
the net increase in Trp fluorescence (after blank subtraction and dilution 
corrections) that follows the interaction with the membrane (section 2.4.3). A 
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second PFO derivative was then added to the same cuvette and incubated for 
another 20 min at 37 ºC and the final fluorescence was determined. The Trp 
emission intensity of the sample was recorded, and the fluorescence increase 
calculated from as the difference between the emission before and after 
incubation with the second PFO derivative. The Trp fluorescence corresponding 
to the unbound second derivative was determined in a separate cuvette in the 
absence of membranes. The binding of the second PFO derivative was then 
determined using the increase in the Trp fluorescence as described above.  
3.4.10 Sequential binding of PFO derivatives determined by 
ultracentrifugation 
Sequential binding of two pPFO derivatives was tested using 
ultracentrifugation to separate the bound and unbound protein. Binding of pPFO 
or pPFO
-D434S
 was determined by using one protein labeled with Alexa 488.  Four 
reactions were set up, in which the proteins were bound sequentially. Two of the 
reactions were when the pPFO was bound first and the remaining two more were 
when the pPFO was bound second. In each reaction, only one protein was 
fluorescently labeled.  Reaction involved one protein (200nM) being added to 
liposomes 200 µM in HBS (50 mM HEPES, 100 mM NaCl, pH 7.5) 
and incubated for 20 min at 37 ºC, follow by the addition of the second protein 
and a second identical incubation.   Controls of labeled protein without liposomes 
and unlabeled protein with liposomes were also done.  Each reaction mixture was 
then centrifuged for 1 hr at 95000G using a Beckman optima MAX TL with a 
TLA 120.2 rotor.  Each reaction was then split into three equal fractions: bottom, 
middle, and top. The amount of bound protein was determined by the 
 97 
 
fluorescence of the top fraction. This was assayed using a Fluorolog fluorometer, 
EX 493 nm and EM 520 nm with slit of 2 nm and 4 nm.  
3.4.11 Preparation of cyclodextrin complexed with cholesterol 
Sterol/ MβCD complex solutions of cholesterol in methanol-chloroform 
(2:1 v/v) were added dropwise to a stirred solution of MβCD in PBS on a water 
bath (80 °C) [137]. Once the sterol was added to the MβCD solution, a cloudy 
precipitate formed. Complete dissolution of the sterol was achieved after allowing 
the mixture to stir for about 30-45 minutes. 
3.4.12 Steady-State Fluorescence Spectroscopy  
Steady-state fluorescence measurements were taken using a Fluorolog-3 
photon-counting spectrofluorometer as described previously [105]. Samples were 
equilibrated at 25 
o
C before fluorescence determinations. 
3.4.13 Circular Dichroism (CD) Spectroscopy 
Measurements were taken as previously described [131]. Briefly protein 
sample were made 2 μM in 10 mM sodium phosphate buffer pH 7.5. Five spectra 
were recorded and averaged for each sample. 
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CHAPTER 4 
CONCLUSIONS 
4.1 Future Research 
4.1.1 In vivo cell testing of cholesterol accessibility  
 My work on the development of a probe for cholesterol accessibility has 
opened up a wide range of areas to explore.  The testing done up to this point has 
been mostly focused on proof of concept.  Now that I have demonstrated the 
viability of the probe, there are several outstanding questions that can be 
investigated. The two areas that are the most interesting, as well as promising, are 
the effect of cholesterol reducing drugs on cholesterol accessibility and that of 
cholesterol transport and homeostasis are regulated. 
 Statin drugs are very widely used in cases of heart disease to reduce the 
risk of arterial plaques. They have also been shown to reduce cholesterol serum 
levels in humans.  In several cultured cell types, Lovastatin, a statin drug, has 
been shown to significantly lower membrane cholesterol concentrations by 
approximately a 50% reduction [24-26]. While much is known about statins 
reduction of cholesterol concentration, the effect of the drug class on cholesterol 
accessibility is still unclear and many questions remain to be addressed. The first 
question would be if cells are able to modulate their membrane to maintain 
cholesterol accessibility in the face of reduced cholesterol levels.  It is likely that 
cells will try to compensate for the reduction in cholesterol concentration by 
modulating their membranes to maintain cholesterol accessibility.  An example of 
this would be reducing concentrations of sphingomyelin and other lipids that 
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interact strongly with cholesterol [23, 27] as this will increase the accessibility of 
their reduced cholesterol concentration.   
 Initial testing would take place in cultured cells, which would be exposed 
to increasing levels of Lovastatin.  The effect of the drug on the cell overall 
cholesterol accessibility would be assayed using our probes in conjunction with 
flow cytometry.  The sensitivity of the PFO probes would allow for detection of 
fine change in cholesterol accessibility that could not previously be determined.  I 
would test the cells at many time points, on the order of hours to days after 
treatment with the statin to see how the cell adapts over time to the reduction in 
cholesterol and how long this process takes.  The cholesterol accessibility of the 
cells treated with statin would be compared to untreated cell to determine if they 
recover was partial or complete.  If indeed an adaptation is seen, then the next 
step would be to determine what that adaptation involved.  This would be started 
by looking at concentration of various membrane constituents, specifically those 
that interact strongly with cholesterol like sphingomyelin.  
Cholesterol trafficking, as discussed in section 1.2.6, remains poorly 
understood.  Cholesterol accessibility has been proposed to play a significant role 
in the homeostasis of this system.   One part of this system that is yet to be 
elucidated is how the cholesterol gradient between the ER and the plasma 
membrane is maintained.  As discussed in Section 1.3, while the cholesterol 
concentration of the ER and plasma membrane are very different, their cholesterol 
accessibility is thought to be very similar. It is clear that cholesterol accessibility 
is involved in the regulation of this system.  Through the use of our probes, I aim 
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to determine what this regulation entails.  There are two ways in which I would go 
about this investigation; the first would be to see if cholesterol accessibility 
affects binding of cholesterol transport proteins in vitro. The second would be to 
use kinetics experiment to see which proteins, or methods of vesicular transport, 
effect cholesterol transport and accessibility. 
 The possible cholesterol transport proteins, e.g. SCP-2, would first be 
tested in an in vitro system.  This would be done in a split well plate with 
membranes of different composition in each well. These plates have pores that 
would allow for diffusion of proteins, but not the larger membranes between the 
wells.  A cholesterol transport protein, such as SCP-2, would then be added to the 
system. After the system was allowed to come to equilibrium, I would then 
determine if the transport protein had caused the two membranes to equalize to 
the cholesterol concentration or the cholesterol accessibility. This would be done 
by determination of both the cholesterol concentration through the colorimetric 
assay described in section 2.4.7 and cholesterol accessibility through the using our 
probes.  
This test would be run on membranes containing increasing concentrations 
of sphingolipids in one of the well.  If the transport protein in question uses 
cholesterol accessibility as a means of recognizing cholesterol for transport than, 
as sphingolipids are increased the cholesterol concentration would increases in 
that well but the cholesterol accessibility of both wells will remain constant. If the 
opposite happens and cholesterol concentration remains equal and cholesterol 
accessibility becomes skewed then the transportof cholesterol by the protein is 
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driven by cholesterol concentration.   A number of transport proteins would be 
tested in this way and what drives there transport of cholesterol determined.     
The regulation of cholesterol transport and homeostasis is a very 
complicated and redundant system.  This has hindered progress in determining the 
mechanisms by which it is regulated or even in the exact proteins involved.  In 
previous studies, knocking down anyone one part of the system has shown mostly 
limited effects.  Due to this, I will have to look at how removing one part of the 
system affects the speed of cholesterol transport.  In the initial live cell testing, it 
became apparent that cell whose membrane were loaded with cholesterol would 
equilibrate quickly, if given the opportunity  By testing the kinetics of the 
equilibration of cholesterol accessibility, after either add or removing cholesterol 
to the cell membrane, I should be able to determine the importance of individual 
protein or vesicle transport systems.  
The key to the live cell testing would be the ability to complete it in a 
rapidly and precisely timed manner.  My probe is well suited to this task its 
binding it very fast on the order of seconds to a minute and the cell can be tested 
as soon as the excess probe can be washed away. The transport of cholesterol out 
of the plasma membrane take place on the order of several minutes but this could 
be slowed if necessary by a reduction in temperature.  In this manner, both vesicle 
and non-vesicle transport could be assessed through the use of inhibitors and 
knockdown off specific transporters using RNAi as well as other inhibitors.  
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 I would use any incites gained from the in vitro testing of transport 
proteins to prioritize transport proteins to test.  I would, first, determine how long 
untreated cells require for the equilibration of cholesterol accessibility after a 
standard amount of cholesterol is added.  This measurement would then be 
compared to the same process in the presence of an inhibited transport protein.  
Then, based on the additional time it takes for the system to equilibrate, one can 
rank transport methods in order of importance.   By doing the experiments in this 
manner, the pitfalls of redundant systems that have plagued previous attempts 
should be avoided. The ability of my probes for quick and easy determination of 
cholesterol accessibility levels, makes this finer determination of the effect of 
removing any one pathway from the system possible.   
4.1.2 Creation of a reversible probe using a D4- GFP fusion protein 
My current probe, like all CDC’s, oligomerizes into large ring shaped pre-
pore complexes on the surface of the membrane.  Formation of large oligomers, in 
addition to perturbing the membrane and artificially grouping the probe, is also 
thought to be responsible for the irreversibility of PFO binding. D4, the binding 
domain of PFO, is an isolated domain made up of an eight stranded beta-
sandwich.  If one could isolate just D4, and fuse it to a fluorophore like GFP, one 
would have a monomerically, and reversible, binding probe.  This probe would be 
extremely useful for the assay of dynamic changes in cells inner and outer 
membranes, as well as the ER and other organelles.  This probe could also 
provide insight into the link between oligomerization and the sharp nature of the 
sigmoidal binding curve of the protein.   
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Some work has already been completed towards this goal and is discussed 
in appendix 2.  Our lab currently possesses a PFO-GFP fusion protein that 
contains the entire PFO protein connected to GFP by a peptide linker.   Several 
constructs of the truncated protein have been created and purified with limited 
success as all of the constructs had serious stability issues.  In addition to this, the 
one construct that was finally purified failed to show any binding to high 
cholesterol membranes.  Due to this, it has become clear that a simple truncation 
will not be successful.  
There are several avenues by which this problem can be approached in the 
future.  The first would be to try to mutate the extremely hydrophobic top of D4 
that is now exposed in the fusion protein. The amino acids in this highly 
hydrophobic interface between D3 and D4 are responsible for holding to protein 
together.  When D3 is removed, these amino acids become solvent exposed, and 
therefore, problematic.  I would mutate these amino acids to either a more neutral 
amino acid, such as alanine, or something more hydrophilic, such as threonine or 
lysine.  This should aid with the folding and increase the stability of the protein 
fusion construct.   
The second possible solution would be to try other more stable and faster 
folding GFP constructs.  Our current fusion probe has a standard EmGFP.  I 
would swap out this GFP for one that will aid in the stability of the overall fusion 
construct. Several GFP proteins have been developed that fold and maturated 
faster, as well as, those that have additional outer charges for increased solubility.  
A super folding GFP would allow for low temperature growth of the protein that 
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may help in the proper folding of D4.   A GFP with increased solubility will 
increase the solubility of the overall complex, but will not help if D4 is miss-
folded and nonfunctional.   Careful testing of the cholesterol depended binding of 
the probe will be necessary after these constructs are made.  
 The third solution would be to try a different CDC-D4 that is reported to 
be more stable.  One of our colleagues at a conference indicated that domain four 
from other CDCs is more stable than that of PFO, specificity alveolysin.   While 
this would likely solve the problem, an issue would lie with having to retest all of 
the D4 mutation we have already done.  While alveolysin has a 75/87 identity/ 
similarity (Fig. 1.4) to PFO, the fact that it is more stable indicated that the effect 
of mutation on the cholesterol threshold may not be the same in this protein.  Due 
to the amount of work this would entail, this option if somewhat less desirable.    
 
4.2 Summary  
 As I have illustrated in this work, a new detection method is needed for 
the determination of cholesterol accessibility.  As the scope and importance of 
cholesterol accessibility has become more elucidated, it has become clear that 
cholesterol accessibility plays a vital role in many physiologically systems; the 
most important, and well documented, of which is the regulation of cholesterol 
homeostasis.  Currently, there are no probes available to detect cholesterol 
accessibility.  Testing for cholesterol oxidation has only proved moderately 
useful. While cholesterol oxidase does only bind to accessible cholesterol, the 
oxidation process drastically changes the physical property of cholesterol and 
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greatly perturbs the membrane being tested.  The lack of adequate detection 
methods for cholesterol accessibility allows it to remain as a poorly defined 
membrane property.  A better, more quantitative probe would allow for a clearer 
determination of what cholesterol accessibility represents and the role that is plays 
in many physiological systems.   This is the void that my work, and future work 
on this topic, aims to fill as the creation of better detection methods is paramount 
to expanding our understanding of cholesterol accessibility. 
 Throughout my work I have strived to optimize PFO for the detection of 
membrane cholesterol accessibility.  I have created an almost completely non-
lytic PFO derivative to serve as the scaffold of the probe.  This scaffold is over a 
hundred thousand times less lytic than the parental strain and can be easily labeled 
with a fluorophore for detection via a single cysteine added on the top of the 
protein.   Our lab discovered that mutations to the binding domain could alter the 
cholesterol threshold PFO requires for binding.   By carefully testing dozens of 
mutations on model membranes, I was able to build up a library of mutated PFO 
derivatives with varied effects on the cholesterol binding threshold of the protein.  
I have categorized PFO derivatives which both raise and lower the cholesterol 
threshold the protein requires for binding; with derivatives being able to recognize 
a wide range of over 10 mol% cholesterol in our model system.    
In collaboration with Bernardo L. Trigatti at McMaster University, the 
initial testing of the probe was performed on both live and fixed cells using both 
epifluorescent microscopy and flow cytometry.  I demonstrated that the probes 
responded accordingly when the cholesterol concentration in the cells was 
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artificially raised and lowered using cyclodextrin.   The fixed cells exhibited a 
pattern similar to what had been observed on model membranes.   The live cells, 
though, showed a more moderate response to the cholesterol loading.  The data 
showed a more gradual rise in cholesterol accessibility, with levels never reaching 
the binding threshold of the pPFO-T490A derivative.  From this, I concluded that 
the live cells were able to modulate my attempts to artificially raise the 
cholesterol accessibility through cholesterol loading.  Cholesterol accessibility is a 
tightly regulated parameter of the plasma membrane. Our future testing will need 
to be done on a shorter time scale to see the true effects of cholesterol loading on 
the cholesterol accessibility cell membrane.        
I was also able to show that PFO binding sequesters cholesterol and 
lowers the cholesterol accessibility of the membrane. This fact could be exploited 
to modulate cholesterol accessibility in a cell membrane. Rather than remove 
cholesterol from a membrane, one could simply use PFO probes to reduce 
cholesterol accessibility and trigger a cellular response similar to cholesterol 
removal.  This would be more precise and result in less disruption of the 
membrane than removing cholesterol.   Refinements to the probe will continue, 
but the probe stands ready to be utilized for the intended purpose of assaying 
cholesterol accessibility.   
 The probes that I have created can now be used to detect cholesterol 
accessibility quickly and easily in a large number of systems.  Cholesterol 
accessibility is still an ill-defined term because, up to this point, it was hard to 
quantify its effects in most systems.  Giving the scientific community a means by 
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which to easily assay for cholesterol accessibility will allow for a better 
understanding of the role it plays in many cellular functions.   
There are numerous areas where this tool could be useful, one of which is 
in cholesterol trafficking and homeostasis.  This system has long been shown to 
be controlled by cholesterol concentration but more recently it has been suggested 
that it is cholesterol accessibility that controls this system.  How the stark gradient 
in cholesterol concentration between the ER and the plasma membrane is 
maintained has long been an outstanding question in the field.  With the 
demonstration that both membranes have the same level of cholesterol 
accessibility, a possible, and very plausible, explanation has emerged.  This 
theory is that cholesterol accessibility determines transport between the plasma 
membrane and the ER and not cholesterol concentration.  Through the use of our 
probes, we will be able to quickly assay and detect how perturbation of the 
systems affects cholesterol accessibility. This should allow for the determination 
of what role cholesterol accessibility plays in the maintenance of cholesterol 
homeostasis.  I believe that this endeavor is the future of this project and will 
discuss it in more depth in the Future Directions (section 4.1.1).       
There are several other cellular functions that cholesterol has been shown 
to play an important role in; protein activation is another examples.  Many 
membrane proteins such, as ion channels, are activated by the binding of 
cholesterol molecules. This process is thought to be controlled by cholesterol 
concentration but it is very possible that when cholesterol is sequestered in the 
membrane it is not accessible to activate some of these channels. Our probe could 
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be used to determine whether changes in cholesterol accessibility and activation 
of the channels are linked.  
There are many outstanding questions when it comes to cholesterol 
accessibility and I hope that the probes we have created will help to provide 
answer to some of them.  As this research continues I am excited to see what can 
be determined about cholesterol accessibility as the project moves forward.     
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APPENDIX 1 
SIZE DETERMINATION OF PORE COMPLEXES FORMED 
BY DIFFERENT PPFO DERIVATIVES 
 
Rational: All CDC’s oligomerize into large ring shaped complexes on the surface 
of the membrane.  This oligomerization is thought to aid binding to the 
membrane, and be at least partially responsible for the steep rise in the binding 
curve of the CDCs.  I showed that mutations in D3 meant to effect 
oligomerization and pore formation have affected the cholesterol binding 
threshold of the protein (section 3.2.3). This asks the question, have our mutation 
to D4 changed the cholesterol recognition threshold of the protein or simply 
effected oligomerization, and therefore, the cooperative binding of the protein. It 
became prudent to determine if the D4 mutations I made were having any effect 
on the oligomerization of the protein in terms of size of the pore, shape of the 
pore, or completion of the rings.  I determined that the best method to determine 
the size of the complex was electron microscopy imaging (EM) due to the large 
size of the PFO complex. 
Methods: 
Liposomes were created as described in section 2.4.6 and their binding was tested 
as described in section 2.4.3.   For the EM experiment, 500 nM of the given PFO 
derivative was incubated for 20 min at 23-25°C with 500 µM total lipids.  A drop 
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of these samples was then placed on a carbon grid (CARBON TYPE A 300M 
CU) and allowed to adhere for 1 min. The excess liquid was them removed with 
tissue paper and the samples were stained for 30 sec with 2% uranyl acetate. After 
30 seconds, the excess acid was removed with tissue paper and the grids were left 
to dry for 2 hrs.   The imaging was then done on the JEOL JEM-2000FX 
microscope. 15 to 25 images were taken for each sample with an attempt being 
made to pick images that contained complete rings.   The determination of size 
was done using ImageJ. 
Results/Discussion: 
 Liposomes with cholesterol levels close to the binding threshold of the 
PFO derivatives pPFO and pPFO
D434S
 were created.  These liposomes were then 
tested using intrinsic tryptophan fluorescence to determine which batch gave 
closest to 50 percent pPFO binding.  Based on these data, the 31 mol % and 37 
mol % liposomes were selected as the transition for pPFO
D434S
 and pPFO 
respectively. The 47 mol% derivative was used for full binding of both. 
 The PFO derivatives were bound to liposomes placed on a carbon grid and 
stained with uranyl acetate.   Sample images for each of the samples are shown in 
fig. A1.   The drying of the samples to the carbon grid seemed to have caused a 
large amount of ring breakage, only 15-20% of the rings were complete in each 
sample.  Due to this, and the fact that I had selected for complete rings, I did not 
feel confident determine the percentage of complete to incomplete rings, but the 
samples appeared to be qualitatively similar.   Forty complexes were measured 
and averaged for each sample (Table A1).  There was a slight difference in size 
 111 
 
between the rings created by pPFO and those created by the D434S mutation.  
Due to the fact that PFO oligomers contain a varied number of monomers in each 
ring the error bars are too large to make the difference between the two 
statistically relevant 
 
                
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table A1 Average 
Size nm 
Standard 
deviation  
 Average 
Size nm 
Standard 
deviation    
pPFO 
47 mol % 
36.1 2.0 pPFO
D434S
  
47 mol % 
38.1 2.4 
pPFO  
37 mol% 
36.6 1.6 pPFO
D434S
  
31 mol% 
37.7 2.0 
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Figure A.1 Sample images for EM determination of pore size of PFO 
Derivatives. The oligomeric structure of the indicated PFO derivative were 
formed on liposomes containing the indicated mol% cholesterol and subsequently 
transferred to carbon grids.  The grids were negatively stained with uranyl acetate 
Scale Bar 100 nm.   
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APPENDIX 2 
GFP-D4 FUSIONS 
 
Rational: 
All CDCs, including PFO, oligomerize into large ring shaped pre-pore 
complexes on the surface of the membrane.[138]  It is thought that this is 
responsible for the irreversible binding and cooperative binding of PFO indicated 
by its sharp sigmoidal binding curve.  As detailed in section 1.5, D4, the binding 
domain, and the rest of the protein, including D3, the domain responsible for 
oligomerization [139], are only connected by one poly-peptide chain.  As a result, 
it should be easy to separate the part of the protein that recognizes and binds to 
cholesterol and the part that oligomerizes and forms a pore.   Such a construct 
would contain all of the properties wanted such as monomeric binding, reversible 
binding, and being completely non-lytic.  Similar constructs has been previously 
created[121],[140] , but had some solubility issues. However, the fusion probe 
was able to be purified, and its binding was demonstrated. 
Creation of GFP-PFO fusion protein: 
 Creation and testing of the initial full length GFP-PFO fusion was 
completed by other members of the Heuck lab.  The creation of the construct was 
completed by Dr. Fabian Romano-Cherñac and the purification and testing was 
done by Ms. Lindsey Gouvin.   In brief, the DNA codifying for pPFO was cut into 
an EmGFP construct vector (Invitrogen) using PCR, followed by the addition of 
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two point mutations to create the EmGFP-pPFO
D434S
, and EmGFP-pPFO
T490A
 
derivatives.  These three constructs were then purified using standard lab 
procedures as described section 2.4.1. The constructs purified easily and showed 
no instability issues.  The binding of the probe was then tested on model 
membranes using intrinsic tryptophan fluorescence, as described in section 2.4.3. 
The binding data was similar to that observed with non GFP pPFO derivatives, 
but was slightly shifted, ~5 mol% cholesterol lower. (Figure B.1)  This shift may 
be because of the addition of the GFP or simply due to the cholesterol 
composition of the liposomes created being slightly skewed.  This result would 
have to be confirmed before further uses of these probes could continue.      
Creation of EmGFP-D4: 
 I used the full length EmGFP-PFO construct as a base for the EmGFP-D4 
construct.  The undesired parts (D1-3) of the PFO molecule were simple cut out.  
GFP-D4 fusions had proven to have stability problems in the past; I decided that 
creating several constructs that contained small amount of D3 left in the protein 
may stabilize the protein.  The three constructs are shown in Figure B.2. The 
deletion of the first three domains was completed by using a single step PCR 
mediated deletion method. [141]   Primers were created containing 16 to 20 bases 
from either side of the section to be deleted.  The PCR reaction then extended the 
primer to copy all but the undesired section of the plasmid.    
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Purification of EmGFP-D4:     
 Initial attempts at purification of the EmGFP-D4 were met with some 
complications, mostly due to insolubility and protein precipitation.  Attempts 
were made to purify all three of the constructs as described in section 2.4.1 with 
relatively limited success. My initial work was focused on the constructs with 
linker segments, because of reported instability of the straight GFP-D4 constructs. 
Though, this assumption did not prove helpful as the linkers were found to 
increase the likelihood of the protein to precipitate. 
In the initial purification of both the long and short linkers, the protein was 
found entirely in the insoluble pellet after breaking the cells. A number of 
different growth conditions were tried in an attempted to increase the solubility of 
these fusion proteins.  These included low temperature, high salt, addition of 
proline, and overgrowth.  The overgrowth involved inducing the protein at an OD 
of 1.2 as opposed to the standard 0.6.  In this case, the protein would be produced 
more slowly due to lack of nutrients.  This had the opposite of the desired effect, 
increasing precipitation of the protein.  Proline was added at the time of induction 
to act as a quasi-chaperon, but produced no noticeable effect.  Purifying under 
high salt conditions was moderately successful. The buffers for the IMAC column 
were spiked with 300 mM NaCl. This resulted in a small amount of soluble 
protein, but most of the protein had already precipitated prior to purification and 
was still in the insoluble aggregate.  A low temperature induction (18°C) helped 
the solubility, but lead to the GFP chromophore not maturating. I found that 
raising the temperature of the induction to 37°C for the last 20-30 minutes would 
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result in full maturation of the GFP.  A very small amount of the short linker 
protein was able to be purified, but aggregated upon concentration. At this point, I 
set aside the constructs containing linkers, and focused my attempts at purifying 
the no linker construct.   
The construct with no linker was marginally soluble and only precipitated 
in the dialysis between the IMAC and ion exchange columns due to the low salt.  
To solve the problem, I added 100 mM of NaCl to the dialysis buffer after the 
IMAC column and did three one hour dialysis followed immediately by the ion 
exchange column the same day.  This reduced the degradation and precipitation 
significantly.  This led to a moderate amount of pure, and surprisingly, stable 
protein.  This protein was then tested for binding.   The results were not 
promising, as the protein did not show any binding to liposomes, even one 
containing high cholesterol levels. (Figure B.3)  
As I mentioned in the rational for this appendix, another group has created 
a GFP-D4 fusion which did show binding, although they too had solubility issues.  
This raises the question why did mine fail.  There are only two real differences 
between the two. The first is the GFP they used a standard GFP while ours is an 
EmGFP. It seems unlikely that this would have any effect on the stability of the 
construct.  The difference is only a couple of point mutations around the 
chromophore of the GFP. The other difference is I cut PFO off in the same place 
the other group added a cleavage site between D4 and the GFP. This may have 
aided in folding in some fashion. For further discussion of future work and 
possible solution to these problems see Section 4.2.2 
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 Figure B.1 Binding of Full length GFP-pPFO derivatives Cholesterol 
dependent binding of GFP-pPFO (squares), GFP-pPFO-
D434S
 (circles) and GFP-
pPFO-
T490A
 (triangles) Binding measurements were done as indicated in Fig. 2.2 
Data points are the average of at least two measurements. 
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Figure B.2 Structural representation of D4 truncations. Crystal structure of 
PFO in a ribbon representation showing D4 and the linker region of D3 that was 
added to each construct. 
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Figure B.3 Binding of GFP-D4 no-linker derivative.  The graph depicts the 
cholesterol dependent binding of GFP-D4 no-linker (squares), and nPFO (circles). 
Binding measurements were done as indicated in Fig. 2.2. 
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